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Gold nanoparticles attain an intense focus in biomedical imaging applications due 
to their unique optical properties, facile conjugation with biomolecules, and 
biocompatibility. Although a considerable amount of work towards the development of 
gold nanoparticles has been completed, these promising contrast agents have not yet 
reached the clinic due to several challenges including efficient accumulation at the diseased 
site, sensitivity of detection in vivo, potential adverse effects, and clearance from the body. 
High signal-to-background ratio is required to enhance sensitivity of detection. Because 
near infrared (near-IR) light has the best tissue penetration, contrast agents designed to 
work in this range can significantly increase imaging sensitivity. Moreover, efficient 
targeting of the molecular biomarkers on diseased cells can decrease the required dosage, 
increase the site-specific accumulation, and enhance the imaging sensitivity. Molecular-
specific contrast agents developed in this project use directional attachment of antibody 
molecules to the nanoparticle surface, enhancing the targeting efficacy. Additionally, cell-
based delivery of diagnostic and therapeutic agents is gaining much interest due to the 
immune cells’ special access to the avascular, diseased regions. The contrast agents 
developed in this project enable detection of just a few cells per unit of imaging volume, 
enable multiplex imaging, and open up a possibility for tracking different cell populations 
 viii 
with noninvasive photoacoustic and ultrasound imaging. Finally, the clearance of 
nanoparticles from the body dictates their clinical translation. The in vivo pharmacokinetics 
study along with the proposed in vitro model explored in this project will enable fast, 
reliable, and cost-efficient screening of promising agents and facilitate quick optimization 
of nanoparticles for their potential use in the clinic. 
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Chapter 1: Introduction 
1.1  BACKGROUND 
In the past century, medical imaging has made a revolutionary leap by creating six 
imaging modalities used in the clinic; namely, plain film x-ray and computed tomography 
(CT), magnetic resonance imaging (MRI), single-photon emission computed tomography 
(SPECT), positron emission tomography (PET), ultrasound (US) imaging, and optical 
imaging. [1] The first x-ray photograph, taken by Wilhelm Conrad Rontgen in 1895, 
marked the beginning of the revolution. All other current imaging techniques developed in 
the last century have facilitated the diagnosis and treatment of various anomalies. Inspired 
by x-ray technology, however, only in 1975 did Sir Godfrey Newbold Hounsfield introduce 
the whole-body CT scanner to medical practice. With the advent of the CT scanner, 3D 
whole-body imaging became feasible. Although the introduction of CT along with 
exogenous contrast agents enabled acquiring structural information, it did not necessarily 
provide any functional or disease-specific information.  
In 1974, Raymond Vahan Damadian received the first patent on the concept of 
NMR to “scan” the human body to detect cancerous tissue. In 2003, Paul C Lauterbur and 
Peter Mansfield were awarded a Nobel Prize for the discovery of the MRI. This modality 
enabled detection of cancer based on differential relaxation times of normal and cancerous 
tissue without the use of ionizing radiation.  
Dr. Karl Theodore Dussik published the first paper on medical ultrasonics in 1942. 
Later in 1950, Professor Ian Donald developed a technology and applications for 
ultrasound. The ultrasound technique is non-invasive imaging that uses high-frequency 
sound waves to generate images of soft tissue.  
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The invention of artificially produced radioisotopes by Frederic Joliot-Curie and 
Irene Joliot-Curie in 1934 inspired the commencement of nuclear imaging. Radioactive 
tracers are distributed differently throughout the body as the normal and diseased tissue 
process them differently.  In 1961, James Robertson led the team that invented the first 
single-plane PET scanner at Brookhaven National Laboratory. Soon after, SPECT imaging 
was introduced. Both PET and SPECT show the distribution of radioisotopes and provides 
functional imaging of the tissue. However, none of these imaging techniques give 
anatomical/morphological information about the tissue. The integration of CT with PET 
and SPECT in 2001 and 1999, respectively, enabled combining metabolic sensitivity of 
PET and SPECT with the temporal and spatial resolution of CT.  
Optical imaging uses tissue properties to absorb and scatter light to generate an 
image. Optical imaging involves different techniques including diffuse reflectance,[2] 
photon scattering, [3-5] multi-wavelength spectroscopy,[6] autofluorescence spectroscopy, 
[7] polarization spectroscopy, [8] and optical coherence tomography.[9, 10] This imaging 
modality offers safe, fast, high resolution and high sensitivity imaging with the use of 
molecular-specific contrast agents, although the in vivo imaging capabilities are limited 
due to scattering and absorption of visible light by the tissue. Diffuse optical imaging 
increases light penetration in tissue (up to 10 cm), albeit with reduced resolution. Near 
infrared light can penetrate deeper as body tissue does not scatter this light and the use of 
molecular-specific contrast agents enables highly sensitive high-resolution molecular-
specific imaging. 
Figure 1.1 illustrates the key imaging modalities used in the current clinical practice 
as well as in the pre-clinical setting. Because the need to diagnose different anomalies at 
an early stage to improve prognosis, optical and photoacoustic imaging modalities are 
 3 
gaining much interest in these years. These modalities not only increase sensitivities but 




Figure 1.1 Key molecular imaging modalities used for preclinical and/or clinical 
applications. CT, computed tomography; PET, positron emission 
tomography; SPECT, single photon emission computed tomography, MRI, 
magnetic resonance imaging; MRS, magnetic resonance spectroscopy; IVM, 
intravital microscopy. Blue circle, appropriate contrast agent or molecular 
imaging agent. (Reprinted with permission from ref. [11]). 
Of the current imaging techniques available to a clinician, x-rays, CT, PET, and 
SPECT use ionizing radiation and/or radioactive contrast agents to produce images. 
Ionizing radiation has long been known to have adverse side effects, including an increased 
risk of cancer. [12, 13] Additionally, PET and SPECT imaging offer low resolutions of 
8x8x8 mm and 12x12x12 mm, respectively, and cannot facilitate early detection of 
diseases such as cancer or enable imaging of small metastasis. [14] MRI provides a safer 
alternative with a similar resolution as CT (1x1x1 mm), however, high cost and limited 
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molecular imaging capabilities necessitate further improvement for current clinical 
diagnosis problems.  
Ultrasound imaging is cost-effective, does not use non-ionizing radiation or a 
radiotracer for generating contrast, and has a decent resolution of 1x1x1 mm, however it 
can only provide morphological information. For efficient diagnosis, functional 
information about the state of the disease along with anatomical details is very important. 
More recently, photoacoustic (PA) imaging has been developed where functional 
information can be obtained. Figure 1.2 exemplifies a potential use of PA imaging in a 
clinical setting to reveal disease-specific information. Additionally, molecular-specific 
details can be obtained by utilizing customized optical absorbers that can label diseased 
sites. Through a combination with ultrasound imaging, PA imaging reveals morphological 
and disease-specific information with high resolution. [15-21] PA imaging does not use 
ionizing radiation or require any radioactive tracers to generate images; hence, this 
modality provides a safer alternative to the currently used clinical imaging modalities. In 
photoacoustic imaging, short laser pulses irradiate tissue. Tissue absorbs optical energy of 
the laser and converts it into thermal energy, which causes thermal expansion of the tissue 
proportional to the amount of absorbed optical energy. An ultrasound transducer then 
records this thermal expansion to generate an image. As photoacoustic imaging offers safe, 
cost-effective, non-invasive, real-time and high resolution molecular-specific imaging,[22, 




Figure 1.2 Principles of photoacoustic imaging (PAI) presented for a potential clinical 
application: diagnostic breast imaging by integrated real-time 
photoacoustic/ultrasound imaging. The laser sends nanosecond pulses of 
NIR light through the transducer into the tissue. This light is then absorbed 
inside the tissue (at different levels for each tissue type/component) causing 
a localized transient thermoelastic expansion. This expansion leads to the 
emission of pressure waves (ultrasound), which can be detected by the array 
in the transducer. Finally, a photoacoustic image is calculated and displayed 
in real-time. At the same time, the ultrasound system can be used in its b-
mode to provide structural information about the tissue, in addition to the 
functional/molecular information obtained by PAI, and both images can be 
displayed on the viewing screen together (either next to each other or 
integrated). (Reprinted with permission from ref. [23]).  
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1.1.2 Nanoparticles as imaging agents 
In past three decades, various nanomaterials gained attention for their use in 
biomedical imaging: carbon-based nanomaterials, semiconductor quantum dots and 
metallic nanoparticles. This section briefly discusses these materials and their importance 
in biomedical imaging along with the challenges associated with their potential uses in 
clinical settings. 
Carbon nanoparticles gained specific interest from the biomedical community after 
the discovery of fullerenes[24] and single-walled carbon nanotubes[25] in 1985 and 1991, 
respectively. Fullerenes was explored as stable carrier of radioactive tracers for nuclear 
imaging[26] and Gadolinium for MR imaging[27] because of their resistance to 
metabolism.   More recently single-walled carbon nanotubes (SWNTs) are gaining much 
interest in various imaging modalities because of their unique properties such as 
fluorescence emission in the near-IR range, strong Raman scattering, strong absorbance in 
near-IR region, and strong T2 weighted contrast when metal impurities are present. [28] 
Because of these properties, SWNTs can serve as contrast agents in multiple imaging 
modalities such as near-IR fluorescence imaging,[29, 30] Raman imaging,[31] MR 
imaging,[32-34] PET imaging,[35, 36] SPECT imaging[37, 38], and photoacoustic 
imaging. [39-44] These carbon nanomaterials show promise for facilitating multiple 
imaging techniques based on their physical properties. However, in vivo distribution of 
these carbon nanomaterials shows that they cannot be metabolized by the body, thereby 
staying in the RES organs for a long period of time and potentially causing long-term 
toxicity. [45-48] A study has also shown that long strands of carbon nanotubes can cause 
carcinogenic effects similar to asbestos.[49] Additionally, evidence suggests that these 
materials can cross the blood-brain barrier,[50] which may cause additional challenges if 
the intended purpose is not to use them for brain targeting and imaging.   
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Quantum dots are semiconductor crystalline solids with dimensions in the 1 to 10 
nm range.[51] Following their discovery in the early 1980s,[52, 53] the first demonstration 
of their application in biological imaging occurred in 1998. [54, 55]  Because of their 
stability against photobleaching, capacity for multiplex imaging, and high sensitivity, the 
use of fluorescent quantum dots in biological imaging has exploded in past decade.[56] 
However, the toxicity of quantum dots has restrained their use to in vitro diagnostic 
applications. 
Metal nanoparticle’s history dates back to around 300 A.D. as the Lycurgus cup 
(now housed in the British Museum) demonstrated unique optical effects due to the 
incorporation of gold nanoparticles in glass, although back then they lacked the knowledge 
of nanoparticles.[57] With invention of the electron microscope,[58] many different types 
of colloidal nanoparticles were investigated around the mid-20th century. [59] Currently 
there are multitudes of applications using different metallic nanoparticles including iron, 
silver, and gold.[60] These nanoparticles are reaching the clinic as the imaging and 
therapeutic agents (Table 1.1). Superparamagnetic iron oxide (SPIO) nanoparticles are 
FDA approved as MRI contrast agents since 1996. More recently, gold nanoparticles with 
various surface modifications are approved for their use in clinical trials to facilitate 
photothermal therapy and targeted delivery (Table 1.1). Plasmonic nanoparticles, including 
nanospheres,[61-65] nanoshells,[66-69] nanocages,[17, 70-72] and nanorods,[20, 73-77] 
are of increasing interest to biomedical engineers due to their biocompatibility, facile 
surface modification, and high optical cross section that can provide a high contrast for 
optical-absorption-based imaging techniques. The optical properties of plasmonic 
nanoparticles strongly depend on their size and shape. Spherical nanoparticles absorb 
visible light around the 520 nm wavelength; however, by increasing anisotropy or creating 
a core-shell structure the plasmonic nanoparticles can strongly absorb near-IR light. As the 
 8 
rod-shaped gold nanoparticles have a higher absorption coefficient than that of core-shell 





Table 1.1 Inorganic nanoparticles on the market and in clinical trials (Reprinted with 
permission from ref. [80] ) 
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Visible light is heavily absorbed and scattered by normal tissue; therefore it has a 
poor penetration depth. Near infrared (near-IR or NIR) light is least absorbed by typical 
tissue components like water, hemoglobin, melanin, fat and can be effectively delivered 
deeper in the tissue.[81] Hence, contrast agents that have high absorption in the near-IR 
region can dramatically enhance the signal-to-noise ratio and allow deeper imaging within 
tissue for optical-absorption-based imaging modalities,[77, 82, 83] including 
photoacoustic imaging. [16, 84] This project develops optimized near-IR contrast agents 
for photoacoustic and optical imaging. 
Anisotropic gold nanorods provide a convenient combination of properties for 
biomedical applications.[85-87] Plasmon resonances of gold nanorods can be easily tuned 
in the red-to-NIR spectral region by changing the aspect ratio[78] that allows simultaneous 
imaging of multiple biomarkers. [76, 88] Strong near-IR extinction cross-sections of 
nanorods have been used for two-photon luminescence[74, 89] and photoacoustic[90-92] 
imaging of thick biological samples as well as for photothermal destruction of cancer cells. 
[93-95] Additionally, anisotropic arrangement of the epidermal growth factor receptor 
(EGFR)-targeted gold nanorods on the surface of cancer cells produces surface-enhanced 
Raman scattering that could be used as a marker of EGFR overexpressing cells.[96] Further 
success in biomedical applications has led to clinical trials with the use of gold 
nanoparticles in head and neck cancer[97] and for the treatment of atherosclerosis.[98, 99]  
 
1.1.3 Molecular-specific imaging and targeting using NPs 
In this section, molecular-specific imaging refers to imaging of contrast agents 
directed to particular molecular markers on diseased cells. This differs from molecular 
imaging [100] in nuclear medicine in which cancerous and normal cells metabolize a 
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radioactive tracer differently, facilitating the detection of tumors using one of the nuclear 
imaging modalities such as PET or SPECT. However, these imaging modalities can use 
molecular-specific targeting by using a molecular-specific radioactive tracer to label the 
cancer cells.[101]  
Molecular-specific imaging offers earlier diagnosis of disease by labeling specific 
cell populations that are overexpressing certain molecular markers. Specifically, molecular 
imaging plays a pivotal role in the detection of a small number of cancer cells such as 
circulating tumor cells, facilitating early indication of cancer metastasis. In addition, 
molecular-specific imaging significantly reduces the dose of contrast agents and facilitates 
high signal-to-background ratio for sensitive and selective imaging. Reduction in 
exogenous contrast agents also reduces the potential dose-dependent side effects as well as 
the cost of imaging. Apparent benefits of molecular-specific imaging and treatment have 
encouraged the biomedical community in recent years to invest more in the development 
of targeted imaging and therapeutic agents. Nanoparticles-based platform offers a 
convenient way to incorporate targeting, therapeutic, and multimodal imaging capabilities 
by integration of different functional components to design multifunctional nanoparticles 
(Figure 1.3). Multifunctional nanoparticles can be designed by incorporation of the 
imaging and therapeutic agents within liposomes, micelles, or a silica matrix. Alternatively, 
nanoparticles such as gold or iron oxide providing primary imaging contrast can be 





Figure 1.3 Schematic diagram of multifunctional nanoparticles. Multifunctional 
nanoparticles can be generated by either combining nanocrystals with 
different functionalities or combining nanocrystals with functional small-
molecule cargos through different surface engineering strategies. Four 
typical coatings developed for inorganic nanocrystals are (a) liposome or 
micelle encapsulation, (b) mesoporous silica coating, (c) layer-by-layer 
assembly, and (d ) surface modification. Abbreviations: GNP, gold 
nanoparticles; HfO, hafnium oxide nanoparticles; MNP, magnetic 
nanoparticles; QD, quantum dot; UCNP, upconversion nanoparticles. 




Although the multiple drugs based on nanoparticle platforms for cancer treatment 
have been approved for clinical use do not have targeting capacity yet, the importance of 
targeting for drug efficacy is revealed by multiple ongoing clinical trials that use 
transferrin,[102] antibody fragment,[103] or peptide as targeting ligands for cancer cell 
markers. [104] Multiple targeting moieties such as antibody, antibody fragments, peptide, 
aptamer, affibody, and small molecules targeting specific receptors can facilitate targeting 
of drugs or nanoparticles to the specific biomarker on the cancer cells or on the tumor 
vasculature. [105] Gold nanoparticles are explored as a contrast agents for CT, MRI, 
fluorescence, SERS, photoacoustic imaging, and optical imaging due to their x-ray 
attenuation capability, strong light absorption, intrinsic fluorescence, or incorporation of 
other contrast generating molecules in gold nanoparticles. [106-108] Apart from their use 
as multimodal contrast agents, various research groups perform molecular-specific 
imaging using gold nanoparticles. [109-115] The molecular-specificity translates to the 
clinic as revealed by the use of gold nanoparticles conjugated with recombinant human 
tumor necrosis factor (rhTNF) alpha, facilitating tumor targeting in recent clinical trials 
with no toxic effects at the highest dose tested, which was three-fold higher than the 
previously-established maximum tolerable dose (MTD) for rhTNF alone. [116]  
1.1.4 Cell tracking with nanoparticles 
Cell tracking plays a vital role in cell-based therapy, regenerative medicine, 
unfolding pathologies of different diseases, as well as in understanding trafficking of cells 
during different disease stages. Immune cells such as microphages play a dual role in 
specific diseases such as cancer. Tumor-associated macrophages can reach otherwise 
inaccessible areas of the necrotic core and play an essential role in tumor growth. Labeling 
immune cells with the contrast and therapeutic agents not only unfolds the mystery of how 
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these cells traffic within tumors but also provides a tool to deliver the therapeutic agents to 
eradicate the surviving cancer stem cells in the hypoxic tumor regions.  
A surge in cell-based therapy in early stage clinical trials necessitates safe and 
reliable methodologies to track cells in order to predict their in vivo fate and therapeutic 
outcome. [117] Advances in the nanoparticles-based cell tracking involve use of iron oxide 
nanoparticles for MRI, [118, 119], gold nanoparticles for CT imaging, [120, 121], various 
radionucleotides for PET and SPECT imaging, [122] [123] and microbubbles for 
ultrasound imaging. [124, 125] Considering the risk of ionizing radiation for CT and 
nuclear imaging and the excessive cost of MRI imaging, this project does not investigate 
these modalities. Gold nanoparticles in this project are developed as multimodal contrast 
agents facilitating in vivo cell tracking using noninvasive photoacoustic and ultrasound 
imaging along with ex vivo validation capabilities using fluorescence imaging.  
 
1.1.5 Clinical translational of nanoparticles 
Clinical translation of nanoparticles as contrast agents depends on multiple factors 
including biocompatibility, blood half-life, signal-to-background ratio, and clearance of 
nanoparticles within a reasonable timeframe after imaging. Figure 1.4 illustrates the fate of 
nanoparticles after administration and the potential toxicity during their absorption, 
distribution, metabolism and excretion (ADME). Carefully tailored nanoparticles having 
desirable pharmacokinetics can facilitate clinical translation.  
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Figure 1.4 An illustrative scheme for the pharmacokinetics of extraneous nanoparticles 
in vivo and possible toxicities that may arise. Nanoparticles, after delivered 
into the body, undergo the process of pharmacokinetics. They are absorbed 
and brought into the bloodstream where nanoparticle–serum protein 
interactions frequently occur. Then they spread into tissues and organs via 
tissue-specific extravasation from the bloodstream. Afterwards, they may be 
metabolized in the liver by cytochrome P450 enzymes and some may start 
metabolic process early in the gastrointestinal tract. Finally, the remnant 
nanoparticles will be removed from the body via the kidney (urine) or bile 
(feces). At each step of this process, toxicity may arise. Among them, 
hematological abnormality, organ toxicity and immunotoxicity arise from 
the long-term retention of nanoparticles in the liver, lung, spleen and kidney. 
Moreover, nanoparticles may cross the biological barrier system (blood–
brain barrier, placental barrier, etc.) and neurotoxicity, reproductive toxicity 
may be induced. Genotoxicity may also appear. In addition, nanoparticles 
probably disturb the normal metabolic functions and induce metabolic 
abnormality. (Reprinted with permission from ref. [126]).  
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Toxicity of the gold nanoparticles depends heavily on their size, surface coating, 
and surface charge. Well-investigated physical properties of these nanoparticles have led 
us to produce biocompatible formulations for biomedical imaging applications. [126-129] 
The nanoparticles less than 5-nm in size clear efficiently through RES; however, they do 
not have enough blood residence time to allow successful accumulation in the organ of 
interest. [130, 131] However, the larger nanoparticles with enough blood residence time 
after proper surface modifications tend to accumulate in the clearance organs. [132] 
Recent clinical trials represent great potential for plasmonic nanoparticles to be 
clinically relevant, [97-99, 116] but widespread use of these agents is still questionable 
because of their long-term accumulation in RES (reticuloendothelial system). [132-134] 
Although the use of these nanoparticles does not cause acute toxicity after optimized 
design,[135, 136] the clearance of any foreign material is highly warranted for their 
successful translation to the clinic. A major determinant of the clearance of non-degradable 
nanoparticles is their exocytosis from the cells of different organ, facilitating their eventual 
renal clearance or clearance through the bile and reducing their long-term toxicity. Table 
1.2 summarizes current literature on exocytosis of different types of nanoparticles from 
different cells. Vast body of the literature suggests that the size and surface characteristics 
of the nanoparticles along with the exocytosis environment and the type of cells play a 
crucial role in the excretion of nanoparticles. Biodegradable gold nanoclusters synthesized 
using 5-nm primary gold nanoparticles can impart enough blood residence time for 
imaging, and have the potential to clear through RES after biodegrading in the acidic 
environment of the cells. [137, 138] With strong near-IR absorbance, the gold nanoclusters 
can also be imaged using noninvasive photoacoustic imaging modality in vivo. [139] The 
final part of this dissertation evaluates gold nanoclusters for their clinical translation 
potential.  
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* AuNSs – gold nanospheres, AuNRs – gold nanorods; NPs – Nanoparticles, PS – 
polystyrene NPs, PLGA –  poly(lactic-co-glycolic acid) NPs, BSA – bovine serum 
albumin,  LEVs – logic-embedded vectors, OEG – monocarboxy (1-mercaptoundec-11-
yl) hexaethylene glycol, MSNs – Mesoporous silica nanoparticles, LY – lucifer yellow, 
QDs – quantum dots 
£  STO – fibroblast cells, HeLa – ovarian cancer cells, SNB19 – brain tumor cells, A549 – 
human lung cancer cells, VSMCs – human arterial vascular smooth muscle cells, 
OVCAR-3 – human ovarian cancer cells, HUVECs – human umbilical vein endothelial 
cells; H1299 – human lung cancer cells, NE083 – human esophageal epithelial cells, 
3T3-L1 – pre-adipocytes, 489-2.1 – multipotent stromal cells, HepG2 – liver hepato 
carcinoma cells, IMR-90 – Normal human lung fibroblasts, U251 – Human glioblastoma 
cells 
€ FM – Flurescent microscopy, GPC – gel permeation chromatography, FLA – Flow 
cytometric analysis, CFM – confocal microscopy, FS – fluorescence spectroscopy, FAAS 
–  flame atomic absorption spectrometry, ICP-AES – Inductively coupled plasma atomic 
emission spectroscopy, ICP-MS – Inductively coupled plasma mass spectrometry, HPLC 
– High-performance liquid chromatography  
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1.2  DISSERTATION SUMMARY 
A surge in the laboratory-based production of a variety of promising nanoparticles 
is not yet leading to their use in the clinic for two main reasons: 1) the sensitivity of 
detection in vivo and 2) toxicity and adverse side effects. By directly addressing these 
problems, this dissertation builds upon current literature and facilitates clinical translation 
of nanoparticles. First, the sensitivity of detection in vivo can be enhanced by obtaining a 
high signal-to-background ratio and ensuring effective accumulation of contrast agents to 
the disease site. Toxicity and adverse side effects caused by nanoparticle use can be taken 
care of by ensuring biocompatibility during systemic circulation, lowering dosage for 
imaging, and ensuring efficient clearance after the imaging procedure. Chapter 2 develops 
molecular-specific contrast agents with high specificity and contrast in photoacoustic 
imaging to ensure efficient targeting of diseased areas and increasing the signal-to-
background ratio. Chapter 3 explores an alternate means of contrast agents’ delivery and 
enables tracking of cells with very high sensitivity in a tissue-mimicking environment to 
detect just a few cells per unit imaging volume. Both chapters 2 and 3 further the 
translational research by providing molecular-specific contrast agents for targeted imaging 
as well as multiplex cell tracking capabilities with high sensitivities (Figure 1.5). Chapter 
4 evaluates pharmacokinetics of biodegradable contrast agents and develops an in vitro 
model for high throughput screening of promising contrast agents to predict their in vivo 






Figure 1.5 Schematic of relevance of different parts of this dissertation towards 
facilitating translation of the nanoparticles-based contrast agents from the 
laboratory to the clinic 
 
Chapter 2 develops molecular-specific gold nanorods with tunable absorbance in 
near-IR range to facilitate in vivo imaging using noninvasive photoacoustic and ultrasound 
imaging. Current literature involves antibody attachment to nanorods with non-directional 
approaches involving electrostatic or covalent attachment where the antibodies can attach 
to the nanorod surface in any orientation leaving some of the attached antibodies unable to 
bind to their target because of the hidden antigen-binding regions. Additionally, 
characterization of nanorods after different conjugation procedures is not well documented, 
making it difficult to know if the nanorods are of good quality without significant 
aggregation after different modifications. Nanorods developed in this chapter maintain 
high quality after different modifications along with directional attachment to antibodies. 
The nanorods are conjugated by covalently attaching the Fc portion of the antibody to the 
nanorods’ surface, leaving antigen-binding sites available for targeting. Moreover, by 
attaching the Fc portion to the nanorod surface, the molecular-specific nanorods can have 
prolonged blood residence time because they escape Fc receptors-mediated uptake by 
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macrophages, thereby increasing accumulation in the targeted site. These molecular-
specific near-IR contrast agents are evaluated using optical and photoacoustic imaging in 
a tissue-mimicking environment. 
Chapter 3 optimizes multi-modal near-IR contrast agents for immune cell tracking 
using noninvasive photoacoustic imaging. Upon cellular uptake, the gold nanoparticles 
plasmon couple due to aggregation in the cellular endosomes, thereby broadening the 
absorbance spectra of the nanoparticles. Gold nanorods with different aspect ratios have 
distinct longitudinal absorbance peaks in the near-IR range and therefore can facilitate 
multiplexing to track different cell populations. Plasmon coupling upon endosomal uptake 
hinders the feasibility of multiplexing. Moreover, current literature suggests low uptake of 
rod-shaped nanoparticles compared to spherical nanoparticles by macrophage cells that 
may again impede efficient tracking of labeled cells. In addition, the current limitation of 
imaging lies in the sensitivity of detection. This chapter develops a strategy for changing 
the shape of gold nanorods by coating them with silica to increase macrophage uptake. The 
silica-shell not only enhances cellular uptake of nanorods by changing their morphology, 
but also prevents plasmon coupling of gold nanorods after cell uptake, facilitating 
multiplexing. The silica matrix also incorporates fluorescent dye by covalent linking and 
provides added imaging capability for ex vivo validation. Moreover, this chapter 
demonstrates the feasibility of detecting only a few cells per unit imaging volume using 
photoacoustic imaging of a tissue-mimicking gelatin phantom encompassing different 
concentration of cells loaded with fluorescent silica-coated gold nanorods.   
Chapter 4 evaluates biodegradable gold nanoclusters for their in vivo 
pharmacokinetics and develops an in vitro screening method for predicting the uptake of 
nanoparticles by the RES organs. A major limitation in clinical translation of plasmonic 
nanoparticles includes their clearance after systemic administration. Current literature 
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reveals that nanoparticles accumulate in the liver and spleen for long periods, potentially 
causing long-term toxicity. This chapter evaluates the clearance kinetics of biodegradable 
gold nanoclusters in normal mice. Furthermore, an in vitro screening model is developed 
where the clearance kinetics from the major phagocytic cells in the liver is investigated and 
compared with in vivo results to deduce the fate of novel nanoparticles after systemic 





Chapter 2: Molecular-Specific Contrast Agents† 
2.1 INTRODUCTION 
Imaging of diseased region is better accomplished by using a contrast agent that is 
specifically designed to label the diseased cells.[157] This molecular specificity is obtained 
by attaching a biomarker-specific protein to the contrast agent. Upon injection of such 
contrast agent in the body, the molecular-specific contrast agent would only bind to the 
particular biomarker on diseased cells. The benefits of using molecular-specific contrast 
agents are high signal-to-background ratio for imaging a diseased region, low dosage 
necessary to achieve high imaging sensitivity, and reduced toxic effects due to lower 
dosage of injected agent. Furthermore, while performing therapy along with imaging, the 
molecular-specificity can reduce adverse side effects of therapy to healthy tissue. 
Plasmonic gold nanoparticles have become an area of intense focus in biology and 
medicine due to their small size and intrinsic properties that offer the potential to solve 
otherwise intractable problems.[17, 63, 66, 67, 70, 93, 109, 158-178] In general, plasmonic 
nanoparticles are intrinsically multimodal contrast agents since they exhibit strong 
scattering and absorption cross sections as well as non-linear optical phenomena such as 
two-photon luminescence and second harmonic generation when excited at the plasmon 
resonance frequency. Gold nanoparticles provide high contrast in cellular and tissue 
imaging using confocal reflectance microscopy,[158, 179] dark-field imaging,[109, 179-
182] two-photon luminescence[74, 89, 183] phase-sensitive OCT,[63] and photoacoustic 
imaging.[17, 18, 64, 166, 184-189] Furthermore, gold nanoparticles have been used to 
                                                 
† Adapted with permission from P. P. Joshi, S. J. Yoon, W. G. Hardin, S. Y. Emelianov, K.V. Sokolov  
Bioconjugate Chemistry, 2013, 24(6), 878-888. Copyright 2013 American Chemical Society. Contribution 
of the coauthors – S. J. Yoon performed photoacoustic imaging of the phantom, W. G. Hardin performed 
XPS on prepared samples, S. Y. Emelianov supervised imaging part of the paper, K. V. Sokolov provided 
overall supervision of the research. 
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transform light energy into heat in photothermal therapy of cancer either by using near-IR 
(NIR) absorbing gold nanoshells,[66-69] nanorods,[93] and nanocages[70, 72, 190] or by 
applying molecular-targeted spherical nanoparticles which undergo molecular-specific 
aggregation upon interaction with cancer cells that results in strong absorption in the  red- 
to NIR-spectral region due to plasmon resonance coupling.[165, 191]  The use of NIR 
irradiation is essential for  in vivo applications because NIR light has the best tissue 
penetration depth.[192, 193] In recent developments, gold nanoparticles have been 
explored as carriers of nucleic acids such as siRNA or antisense DNA molecules that can 
be selectively activated or released using light irradiation, which results in remotely 
triggered gene silencing.[65, 194, 195] 
Among all available nanoparticle geometries anisotropic gold nanorods provide a 
convenient combination of properties for biomedical applications.[85-87]   Plasmon 
resonances of gold nanorods can be easily tuned in the red-NIR spectral region by changing 
the nanorod aspect ratio[78] that allows simultaneous imaging of multiple biomarkers.[76, 
88] Strong NIR extinction cross-sections of nanorods have been used for two-photon 
luminescence[74, 89] and photoacoustic[90-92] imaging of thick biological samples as 
well as for photothermal destruction of cancer cells.[93-95] It was also observed that 
anisotropic arrangement of epidermal growth factor receptor (EGFR) targeted gold 
nanorods on the surface of cancer cells produces surface-enhanced Raman scattering that 
could be used as a marker of EGFR overexpressing cells.[96] Furthermore, the anisotropy 
property of nanorods has been explored for dynamic imaging of rotational motion in 3D 
space.[196] 
    We have evaluated feasibility of imaging gold nanorods using combined 
intravascular ultrasound (IVUS) and intravascular photoacoustic (IVPA) imaging in rabbit 
model (Figure 2.1). A balloon injured New Zealand white rabbit was injected with 
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PEGylated gold nanorods and the aorta was excised 26-hours post administration for ex 
vivo imaging.[197] Imaging was performed by Doug Yeager from Dr. Emelianov’s lab and 
the PEGylated gold nanorods were prepared by Pratixa Joshi. Clearly, the nanorods, 
accumulated by the macrophages in the aorta, can be imaged using combined IVUS and 
IVPA imaging in either saline or blood environment. While this study demonstrated the 
feasibility of detecting gold nanorods imaging in vivo using photoacoustic imaging, 
molecular-specific contrast agents are required to enhance specificity and sensitivity of 




Figure 2.1 Three-dimensional integrated intravascular ultrasound and intravascular 
photoacoustic (IVUS/IVPA) renderings of gold nanorod (AUNR)-labeled 
atherosclerotic plaque (color online). (a) Combined IVUS/IVPA rendering 
of an 8-mm long section of atherosclerotic rabbit artery obtained through 
saline. (b) Photograph of the corresponding artery section revealing AUNR 
distribution at the luminal surface (red). Combined IVUS/IVPA images 
obtained through saline (c), and through blood (d) of aseparate 6-mm 




Surface modification of nanoparticles is critical for both in vitro and in vivo 
applications, as uncoated nanoparticles are colloidally unstable and often cytotoxic in 
biological solutions.[75, 198-200]  Conjugation of biomolecules to nanoparticles furnishes 
important properties needed for biomedical applications, such as molecular targeting, 
stealth properties and surface charge. Antibodies are the most widely used targeting 
moieties due to their high affinity and availability for a large number of established 
biomarkers. 
Bioconjugation of gold nanorods is confounded by the presence of surface layer of 
cetyl trimethyl ammonium bromide (CTAB).[201] In commonly used synthesis of highly 
uniform gold nanorods, the CTAB molecules promote crystal growth in one direction 
resulting in rod-shaped particles.[202] CTAB is stabilized on gold surface as a bilayer by 
electrostatic interactions between gold and CTAB as well as by hydrophobic interactions 
within bilayer of CTAB molecules. A recent review by El Sayed’s group[86] summarizes 
current methods of nanorods bioconjugation: 1) electrostatic adsorption of biomolecules 
directly to the CTAB layer; 2) coating of CTAB layer with one or more layers of charged 
polymers followed by physisorption or covalent attachment of targeting moieties; 3) 
bifunctional ligand attachment where CTAB is first replaced by bifunctional linker 
molecules followed by conjugation of biomolecules; and 4) ligand exchange where CTAB 
is replaced by small thiolated molecules (Figure 2.2). These conjugation methods have a 
number of major shortcomings that need to be addressed in order to further optimize gold 
nanorods for molecular-specific imaging and therapy. In first two approaches, the CTAB 
bilayer is still present on nanorods that can lead to long term cytotoxicity of the 
bioconjugates.[203] In addition, the physisorption approach requires a high concentration 
of antibodies for synthesis of nanoparticle conjugates, results in random orientation of 
antibodies at the gold surface, and can be prone to antibody replacement by other molecules 
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in biological samples.[204] In the third approach, the CTAB bilayer was first replaced by 
small bifunctional linkers with thiol functional groups for interaction with the gold surface 
and carboxyl groups for covalent attachment of antibodies using carbodiimide 
chemistry.[88, 205, 206] In this strategy, antibodies are attached through primary amine 
groups.[207, 208] Because the primary amine groups are present in different regions of 
antibody molecules, including antigen recognition sites in the Fab region, this approach 
does not provide control over antibody orientation on the nanoparticle surface, leading to 
reduced overall activity of the attached antibodies. In addition, this conjugation strategy is 
prone to aggregation because antibody molecules have both the primary amine and the 
carboxyl groups, which can act as crosslinking agents between gold nanoparticles. The 
fourth approach has been used to produce non-specific biocompatible nanorods by 
replacing the CTAB bilayer with biocompatible ligands such as PEG.[209] 
Here we address the shortcomings of previously published conjugation protocols 
by developing directional attachment of antibodies to gold nanorods using a two-step 
method (Figure 2.2). First, the CTAB bilayer on nanorods is replaced with methoxy-
poly(ethylene)glycol thiol (mPEG-SH). Then, thiolated antibody molecules are attached 
via Fc portion that does not have antibody binding sites using ligand exchange with mPEG-
SH. The directional conjugation is achieved by specific reaction of the carbohydrate moiety 
located on the Fc portion of most antibodies with a heterofunctional cross-linker; this 
reaction results in antibodies with a dithiol group located in one specific location – the Fc 
region. The dithiol enables antibody conjugation directly to the gold surface. We showed 
that this method produces stable bioconjugates with no aggregation and no cytotoxicity. In 
addition, it requires significantly reduced amount of antibodies during the synthesis as 
compared to physisorption methods. We also demonstrated molecular-specific optical and 
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photoacoustic imaging of epidermal growth factor receptor (EGFR) molecules in cancer 




Figure 2.2 Schematic representation of gold nanorods bioconjugation procedures from 
left to right: electrostatic adsorption of antibodies to CTAB layer on gold 
nanorods; coating of CTAB nanorods by charged polymers followed by 
electrostatic adsorption of antibodies; replacement of the CTAB layer using 
bifunctional ligands followed by covalent attachment of antibodies; the 
directional conjugation method proposed here that consist of replacement of 
the CTAB layer with mPEG-thiol molecules followed by directional 
attachment of antibodies 
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2.2 RESEARCH APPROACH 
2.2.1 Material and Methods 
Gold nanorods synthesis: Gold nanorods were synthesized by seed mediated growth 
mechanism using the previously published protocol.[202] Briefly, 100 µL of 4 mM AgNO3 
(Acros Organics, 41936) was added to 10 mL of 0.5 mM HAuCl4 (Sigma, 520918) 
dissolved in 0.1 M CTAB (Amresco, 0833) water solution. Then, 70 µL of 78.8 mM 
ascorbic acid (Acros Organics, 401471000) was added to the reaction mixture as a mild 
reducing agent; this constitutes the nanorod growth solution. In parallel, a seed solution 
was prepared by mixing 0.6 mL of 10 mM ice-cold NaBH4 (Fisher, S678) to 10 mL of 0.25 
mM HAuCl4 dissolved in 0.1 M CTAB solution. To initialize the growth of nanorods, 12 
µL of the seed solution was added to the nanorod growth solution within 30 minutes of 
making the seed solution. Then, the reaction mixture was kept at 30oC for at least 2 hours 
for completion of nanorod synthesis. The nanorods were washed twice in water by 
centrifugation at 18000x g for 45 minutes. The final nanorod pellet was dispersed in water 
and stored at room temperature. Nanorods were 20-times concentrated compared to the as-
prepared nanorods. 
Gold nanorods bioconjugation: The nanorods were bioconjugated in two steps (Figure 
2.3). The first step involved replacement of the CTAB layer on nanorod surface with 
methoxy-PEG-thiol (mPEG-SH). One hundred microliters of 0.5 mM mPEG-SH with 
molecular weight 2000 Da (Creative PEGworks, PLS-605) in water were mixed with 1 mL 
of CTAB-NRs (20-times concentrated compared to as-prepared nanorods) and sonicated 
using a water bath sonicator (Branson 1510R-MT) for 30 minutes at room temperature. 
After sonication, free CTAB and mPEG-SH molecules were removed by centrifugation 
using 100 KDa centrifugal filters at 2500xg for 15 minutes. Then, the nanorods were 
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washed one time with water to remove any residual mPEG and CTAB. The prepared 
mPEG-NRs were dispersed in 1 mL water and stored at room temperature.  
In the second conjugation step, the carbohydrate moiety on Fc portion of anti-EGFR 
clone 225 (Sigma, E2156) or RG-16 (Sigma, I0138) antibodies were thiolated following 
previously published protocol developed by our research group.[210] Briefly, antibodies 
were concentrated using 50 kDa MWCO centrifugal filter and were dissolved in 100 mM 
Na2HPO4, pH 7.5 buffer at 1 mg/mL. Then, 10 µL of 100 mM NaIO4 in water was added 
to 100 µL of antibody solution and the mixture was incubated in dark for 30 minutes. The 
reaction was quenched by adding 500 µL of 1x PBS. At this point the carbohydrate 
moieties on the Fc portion of the antibody were oxidized to aldehyde groups.[210, 211] 
Then, 140-times molar excess of heterofunctional linker dithiolaromatic PEG6-
CONHNH2 (SensoPath Technologies, SPT-0014B) was added to the antibody solution. 
The linker has hydrazide and dithiol groups on opposing ends of the molecule. The 
hydrazide moiety interacts with aldehyde groups of the Fc portion of the modified antibody 
molecules. The reaction mixture was incubated at room temperature for 1 hour and then 
the thiolated antibodies were collected using centrifugal filters and resuspended in 0.1 M 
sodium phosphate buffer, pH 7.5. Two hundred microliters of the thiolated anti-EGFR 
antibodies at concentration of 1 mg/ml were mixed with 0.1 mL of mPEG-NRs and the 
suspension was incubated at room temperature for 24 hours under moderate shaking. 
Finally, the antibody-nanorod conjugates were washed twice in 0.1 M sodium phosphate 
buffer (pH 7.5) by centrifugation to remove unbound antibodies. After the final wash, the 
antibody-nanorod conjugates were redispersed in buffer or phenol free cell culture media.  
For fluorescence imaging experiments, the antibodies with oxidized carbohydrate 
moieties were labeled with AlexaFlour dye (Invitrogen, A-20186) before attachment of the   
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heterofunctional linker. The labeling was carried out using antibody-labeling kit purchased 
from Invitrogen.  
 
 
Figure 2.3 Schematic illustration of the directional conjugation synthesis proposed 
here. 
 
Amount of antibodies per nanorod: Gold nanorods were conjugated with fluorescently 
labeled antibodies to quantify the number of antibodies per nanorod. First, a calibration 
curve was plotted by measuring fluorescent emission peak intensity as a function of known 
concentrations of fluorescently labeled antibodies mixed with PEGylated nanorods at 
optical density of 0.1 cm-1. The calibration measurements were carried out in the presence 
of nanorods to account for a decrease in fluorescence signal due to absorbance by gold 
nanorods. Then, suspensions of nanorod conjugates with fluorescently labeled antibodies 
were thoroughly washed from any residual free antibody molecules and were diluted to the 
optical density of 0.1 cm-1 to match the calibration measurements.  The fluorescence 
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emission of the conjugates was measured and the number of conjugated antibodies was 
determined using the calibration curve. To calculate the number of antibodies per nanorod, 
we carefully analyzed the average size of the nanoparticles using transmittance electron 
microscopy (TEM) and the gold concentration using inductively coupled plasma mass 
spectrometry on an Agilent ICP-MS system.  
 
Specificity of molecular labeling: EGFR expressing human A431 cells and EGFR-
negative human MDA-MB-435 cells were cultured in phenol-free DMEM (Invitrogen, 
11039) and MEM (Invitrogen, 41061) culture media, respectively, supplemented with 10% 
fetal bovine serum (FBS) at 37oC in a 5% CO2 environment.  Antibody conjugated gold 
nanorods were incubated with either A431 cells or MDA-MB-435 cells for two hours at 
room temperature at a concentration of approximately 2x106 cells per milliliter of 
conjugated nanorods (at the same nanorods concentration as as-prepared nanorods). 
Unbound gold conjugates were separated from cells by centrifugation at 200x g for 3 
minutes followed by washing cells with fresh cell culture media. The labeled cells were 
characterized by UV-Vis spectroscopy (BioTek Synergy HT) and optical microscopy. 
Bright-field transmittance and fluorescence (Cy5 filter cube, ex/em – 649/670 nm) images 
were taken with Leica DM600 upright microscope, and hyperspectral images were 
acquired using a PARISS spectral imager (Lightform Inc.). For all imaging, 20x 0.5 NA 
objective and 100 W halogen light source were used. The hyperspectral system was 
calibrated using a standard low pressure Hg wavelength calibration lamp (Lightform, Inc.). 
The hyperspectral images obtained from cells were normalized by the lamp spectrum 
obtained from the part of the microscope slide that did not have cells. RGB images were 




Cell viability study: Biocompatibility of nanorods was characterized using MTS assay 
after incubation of A431, MDA-MB-435 and murine macrophage (J774A.1) cells with 
either  0.3 nM CTAB-NRs or PEG-NRs in phenol-free cell culture media supplemented 
with 10% FBS for 6 hours at 37C. After removal of nanorods and washing once with PBS, 
the MTS reagent (mixture of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Promega, G111B) and PMS 
(phenazine methosulfate) (Sigma, P9625) prepared in phenol free cell culture media) was 
added to the cells treated with nanorods and to untreated control cells. Absorbance at 490 
nm wavelength is proportional to the number of metabolically active live cells in a sample. 
Background absorbance before adding MTS reagent was subtracted to calculate cell 
viability.    
 
Tissue mimicking phantom preparation: Gelatin based tissue-mimicking phantoms with 
cell inclusions were fabricated for combined photoacoustic and ultrasound imaging. To 
simulate tissue background, 6 % gelatin solution with 0.1 wt% of 15 µm silica particles 
was used to prepare base and top layers which encapsulated cell inclusions. Specifically, 
suspension of A431 cells only and A431 cells labeled with anti-EGFR gold nanorods were 
prepared at concentration of 4×107 cells/mL. Each cell suspension was mixed with the 
same volume of 12 wt% gelatin solution containing 0.2 wt% 15 µm silica particles at 37oC. 
The mixture of cells and gelatin was placed on the base layer of 6 wt% gelatin with 0.1 




Photoacoustic imaging set-up: The ultrasound and photoacoustic imaging system 
consisted of a microprocessor unit that utilized a custom-built LabVIEW program to allow 
synchronization between the ultrasound pulser/receiver, data acquisition unit, pulsed laser 
and 3D motion axis. Figure 2.4 depicts the imaging set-up used in this study. The images 
were taken using 25 MHz single element focused transducer (f/# = 4, focal length = 25.4 
mm), and the excitation light was delivered by a 1.5 mm diameter optical fiber. A tunable 
OPO laser with 7 ns pulse duration and 10 Hz pulse repetition rate was used to generate 
photoacoustic signal. The 2D ultrasound and photoacoustic images were obtained by 
mechanically scanning over the region of interest with 100 μm lateral step. To improve 
signal-to-noise ratio, 10 photoacoustic A-lines were collected and averaged.  
 
 
Figure 2.4 Schematic of the experimental set-up used to obtain combined ultrasound 
and photoacoustic images 
 
X-ray Photoelectron Spectroscopy (XPS): XPS data was acquired using a Kratos AXIS 
Ultra DLD spectrometer equipped with a monochromatic Al X-ray source (Al α, 1.4866 
keV).  High resolution elemental analysis was performed on the O 1s, C 1s, N 1s, S 2p and 
Au 4f regions with a 40 eV pass energy, utilizing 0.1 eV steps, and dwell time of 4 sec per 
step. Charge compensation was used for the CTAB and PEG controls, in addition to CTAB 
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and PEG-coated nanorods. All absolute energies were calibrated relative to gold, and 
graphite. The peak positions and areas are calculated using a standard sum Gaussian-
Lorentzian fit with a linear (O, C, N, S) or Shirley (Au) background correction. 
 
Determination of CTAB/PEG ratio and CTAB surface coating by XPS: The CTAB to 
PEG ratio on the surface of PEG-coated gold nanorods was determined from the integration 
of the N 1s and O 1s peaks in the XPS spectrum. CTAB molecule contains one N and no 
O atoms, while 2 KDa mPEG-SH has no N and 46 O atoms. As a result we have the 
following relationship between molar fractions of N (yN), O (yO), CTAB (yCTAB) and PEG 
(yPEG) on the PEG-coated nanorods. 
    yN = yCTAB     (I) 
    yO = 46*yPEG     (II) 
Integration of the N 1s and O 1s peaks in XPS spectrum of PEG-nanorods yields 
N/O ratio (yN/ yO) of 0.105. Using this ratio and the above relationships, we determined 
that the molar ratio of CTAB to PEG (yCTAB/yPEG) on the surface of PEG-coated nanorods 
is 4.8. Then, the following equation was used to find the number of surface ligands:  
  NCTAB*fCTAB + NPEG*fPEG = A*0.9    (III) 
where, NCTAB is the number of CTAB molecules on the nanorod surface divided by 
2 because CTAB molecules are present on the surface as a bilayer; NPEG is the number of 
PEG molecules on the nanorod surface; fCTAB and fPEG are footprints of CTAB and PEG 
molecules, respectively; and A is the surface area of a nanorod. Recent report showed that 
the footprint of CTAB on gold nanorods (fCTAB) is ca. 0.27 nm
2.[212] It was shown that 
mPEG molecules can have a  high density packing with fPEG = 12 nm
2 and a low density 
packing with fPEG = 38 nm
2.[213] The factor of 0.9 arises from the approximation of ligand 
attachment as close-packed circles on a planar surface.[214] Considering the 15nm x 40nm 
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gold nanorods used in this study, the calculated amount of residual CTAB on gold nanorods 
after replacement with PEG is 2.3% for low density PEG and 7.1% for high density PEG; 
the CTAB coverage on initial CTAB nanorods is considered to be 100%. 
 
2.3 RESULTS 
Schematic of the conjugation process is shown in Figure 2.3. CTAB-coated gold 
nanorods have high positive surface charge due to presence of the cationic surfactant (Table 
2.1). After replacement of CTAB with mPEG-SH the surface potential decreases from 50 
mV for CTAB-coated nanorods to approximately 8 mV for mPEG-coated nanorods. These 
values correlate well with previously published literature [209] showing the same decrease 
in zeta potential after modification of nanorods with mPEG-thiol molecules. TEM images 
of CTAB-coated and PEG-coated nanorods show no change in morphology of nanorods 
after removal of CTAB layer (Figure 2.5, A).  
 
 
Type of nanorods Zeta potential, mV 
CTAB-NRs 50.34 ± 0.8 
PEG-NRs 8.33 ± 0.46 
225-NRs -16.26 ± 1.55 
RG16-NRs -24.34 ± 0.54 
Table 2.1 Changes in surface charge of gold nanorods after modifications with mPEG-
thiol molecules and with antibodies. 
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Figure 2.5 A) Transmittance electron microscopy images of as-prepared CTAB-coated 
gold nanorods (left) and the nanorods after modification with mPEG-thiol 
molecules (right). B) Extinction spectra of as-prepared gold nanorods (blue) 
and the nanorods after modification with 2 kDa mPEG-thiol (red), clone 
c225 (purple) and RG16 (green) antibodies. c) Comparison of extinction 
spectra of as-prepared gold nanorods (blue) and nanorods after ligand 
exchange using small molecular weight, 356 Da MW, mPEG-thiol 
molecules (orange). Aggregation of nanorods is evident from profound 







To confirm that CTAB was replaced by PEG, high resolution X-ray photoelectron 
spectroscopy (XPS) was performed on CTAB-coated and PEG-coated nanorods. A similar 
analytical analyses was recently reported by Griesser et al.[215] The C 1s, O 1s, N 1s, S 
2p and Au 4f core level spectra from nanorod samples and from pure CTAB and PEG were 
collected and analyzed. The spectra for CTAB-coated nanorods showed four core level 
regions: O 1s (1.5 rel. at.%), C 1s (92.5 rel. at.%), N 1s (4 rel. at.%) and Au (2 rel. at.%) 
(Figure 2.6). The C 1s spectrum consisted principally of (-CH2-CH2-)n functionality (285 
eV), but displayed slight asymmetry. The very low signal from Au is most likely due 
photoelectron scattering in the dense CTAB bilayer. The spectra of PEG-coated nanorods 
revealed five core levels: O 1s (19 rel. at.%), C 1s (65 rel. at.%), N 1s (2 rel. at. %), S 2p 
(1 rel. at. %) and Au 4f (13 rel. at.%). The C 1s spectrum of PEG-coated nanorods differed 
greatly from that of CTAB-coated particles. The spectrum showed two peaks 
corresponding to two chemical states (Figure 2.6). The deconvolution of these two peaks 
revealed PEG functionality ((-CH2-CH2-O2-)n 286.5 eV, 60 rel. at.% of C 1s) and CTAB 
functionality ((-CH2-CH2-)n, 285 eV, 40 rel. at.%) (Figure 2.6). Additionally, an order of 
magnitude increase in O 1s signal at 532.8 eV, interpreted as a C-O functionality, clearly 
demonstrates the presence of (-CH2-CH2-O-)n repeat units of PEG molecules.[216] 
Furthermore, the increase in Au signal indicates that the Au 4f core level photoelectrons 
experience less scattering events. This is consistent with the exchange of the CTAB bilayer 
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Figure 2.6 A) Survey scans of CTAB-NRs and PEG-NRs from XPS measurements; B) 
C 1s core spectra for CTAB, CTAB-NRs, PEG-SH and PEG-NRs. The 
PEG-NR spectrum shows contributions of C-O and C-C bonds. Electronic 
shift observed for CTAB-NRs as compared to pure CTAB is likely due to 
interactions between Au and CTAB whereby gold is more electron 
withdrawing. Such shifts are characteristic of oxidation, indicating that the 
CTAB ligand on the nanorods is partially oxidized. C) Overlay of C 1s 
spectrum for PEG-NRs and additive convolution of C-O and C-C spectrum 
to show the degree of agreement between the XPS collected spectra and the 
deconvolution. 
 
The percentage of residual CTAB molecules after replacement with PEG was 
calculated using the XPS data and previously reported footprints of mPEG polymers[213] 
and CTAB molecules.[212] Because mPEG molecules can attach to surfaces at a high 
(brush conformation) or a low (mushroom conformation)[213] densities, the residual 
amount of CTAB on nanorod surface can vary from ca. 2.3% to 7.1% as compared to the 
initial CTAB surface coating for low and high PEG density, respectively (see Methods 
section for detailed calculations).  The corresponding changes in zeta potential from ca. 
+50 mV for CTAB nanorods to ca. +8 mV for PEG nanorods suggest a high-density 























PEG-NRs: C 1s spectrum
PEG-NRs: Additive
convolution of C-O and C-C
fit
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measurements indicate approximately 16% of residual positive charge on the surface of 
PEG-coated nanorods as compared to CTAB nanorods while XPS measurements show 
7.1% of residual CTAB surface coverage for a high density PEG confirmation. This 
discrepancy might be due to an increased contribution to positive zeta potential by the 
CTAB molecules adjacent to the gold surface in a CTAB bilayer that is disrupted by PEG 
molecules.  
After completion of CTAB replacement with mPEG-SH, dithiol-linked antibodies 
were added to the PEGylated nanorods. The linker was attached to the Fc antibody moiety 
to achieve directional conjugation on the gold surface. Two types of antibodies were used 
in this study: EGFR specific clone 225 and non-specific anti-rabbit IgG clone RG-16. 
Conjugation of antibodies decreases zeta potential to -16 and -24 mV in the case of clone 
225 and clone RG-16, respectively (Table 2.1). The observed negative zeta potential after 
modification with antibodies correlate well with literature[217] and provide indirect 
evidence of antibody conjugation. We achieved 6.5 ± 1.8 antibodies conjugated per 
nanorod based on fluorescence emission spectra of nanorod-conjugates prepared with 
fluorescently labeled antibodies.  
Extinction spectra show ca. 8 nm blue shift in the longitudinal peak of PEGylated 
nanorods as compared to CTAB-nanorods with no peak broadening (Figure 2.5, B). 
Attachment of antibodies results in approximately 6 nm red shift of the longitudinal peak 
relative to the PEGylated nanoparticles for both 225 and RG-16 modified nanorods. The 
observed spectral shifts can be attributed to changes in the refractive index of the local 
environment surrounding the nanorods. This effect has been well documented in the 
literature.[218, 219] The spectral characterization also provides an important and simple 
way to monitor possible aggregation of plasmonic nanoparticles during a conjugation 
procedure. This process can be easily monitored using characteristic spectral changes 
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associated with nanorod aggregation that include three major features: significant 
broadening, strong red shift of the longitudinal peak and increase in transverse to 
longitudinal (T-to-L) peak ratio (Figure 2.5, C). Molecular-specific nanorods synthesized 
here using proposed conjugation strategy show mean value of T-to-L peak ratio increase 
less than 9 % (Table 2.2). In addition, the full-width at half maximum of the longitudinal 
peak does not increase with the PEGylation or antibody conjugation as evident from Figure 
2.5 (B) and Table 2.2. These spectroscopic data confirm that nanorods do not aggregate 
during conjugation with antibodies. 
 
 
 FW at HM, nm 
% increase in transverse 
to longitudinal peak ratio 
CTAB-Nanorods 109.7 ± 7.4  
mPEG(2K Da)-
Nanorods 
100.5 ± 7.5 8.1 ± 2.1 
225Ab-Nanorods 107 ± 4.6 8.9 ± 2.8 
mPEG(356 Da)-
Nanorods 
337.3 ± 66.1 277.4 ± 44.0 
Table 2.2 Spectral characteristics of plain gold nanorods and conjugates of gold 
nanorods. 
 
It is important to note that the molecular weight of mPEG-SH molecules used to 
replace CTAB layer during the first conjugation step is very important. In this study, 2 KDa 
mPEG-SH was used to produce stable molecular-specific nanorods. The use of lower 
molecular weight (356 Da) mPEG-SH led to nanoparticle aggregation as evident from 
significant broadening and a more than 100 nm red-shift in the longitudinal peak with more 
than 250% increase in the T-to-L peak ratio (Figure 2.5, C and Table 2.2). The use of higher 
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molecular weight (5 kDa) mPEG-SH resulted in stable nanorod suspensions. However, 
attempts to conjugate antibodies to these nanorods failed as they did not label EGFR 
expressing cells. This can be attributed to a steric hindrance effect that did not allow 
antibodies to replace high molecular weight PEG molecules from nanorod surface.  
CTAB-coated gold nanorods are known to have cytotoxic effects.[220, 221] 
Therefore, we characterized cellular toxicity of nanorods after replacement of CTAB with 
mPEG-SH molecules. The cell viability study was performed using two different cancer 
cell lines (EGFR expressing A431 and EGFR negative MDA-MB-435) and a macrophage 
cell line (J774A.1). As expected, the CTAB-coated nanorods were highly toxic in all cell 
lines (Figure 2.7). Replacement of CTAB with mPEG-SH resulted in biocompatible 
nanorods, which did not exhibit any cytotoxic effects in any of the cell lines studied (Figure 
2.7).   
 
 
Figure 2.7 Cytotoxicity of as-prepared CTAB-coated and 2 kDa mPEG-thiol coated 
nanorods in different cell lines. The y-axis shows normalized cell viability. 
The viability of control samples is normalized to 100. Values statistically 
different (p < 0.05) from controls are labeled by *; values that do not show 
statistically significant difference from controls (p > 0.05) are labeled by #.  
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Molecular specificity of the antibody-conjugated nanorods was evaluated in two 
cell lines: EGFR-positive A431 and EGFR-negative MDA-MB-435 cells.  Molecular-
specific nanorods were conjugated with anti-EGFR clone 225 antibodies. Nanorods 
conjugated with non-specific clone RG-16 antibodies were used as control. Figure 2.8 
shows dark-field and transmittance hyperspectral images of labeled cells and controls. 
Only EGFR-positive A431 cells labeled with anti-EGFR nanorods show distinct spectral 
signatures in the 500-800 nm range, which corresponds to gold nanorods.  There is no 
detectable difference between unlabeled cells and both the EGFR-positive A431 cells 
labeled with non-targeted RG-16 conjugated nanorods and the EGFR-negative MDA-MD-
435 cells labeled with anti-EGFR nanorods. Conjugates of nanorods with fluorescently 
labeled anti-EGFR antibodies were also used to label both EGFR-positive and EGFR-
negative cell lines; strong fluorescent signal was observed only from labeled EGFR-
positive A431 cells (Figure 2.9). These results demonstrate molecular specificity of gold 




Figure 2.8 Optical characterization of molecular specificity of antibody conjugated 
gold nanorods in cell cultures. Columns from left to right: dark-field 
transmittance images; transmittance hyperspectral images with color-coded 
peak wavelength in 500 - 800 nm spectral region; transmittance 
hyperspectral images with color-coded integrated absorbance in the 500 - 
800 nm region; absorbance spectra integrated over the regions highlighted 
by white squares in the previous column. 
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Figure 2.9 Right – Bright field images; middle – fluorescent images; left – dark-field 
images of A431 EGFR(+) (top row) and MDA-MB-435 EGFR(-) (bottom 
row) cells labeled using nanorods conjugated with fluorescently labeled 
clone 225 (anti-EGFR) antibody. Scale bar = 50 µm. 
Bright-field transmittance images of A431 cells labeled with molecular-specific 
nanorods appear dark compared to unlabeled cells due to light absorption by gold nanorods 
(Figure 2.9). Analysis of dark-field transmittance and hyperspectral transmittance images 
revealed strong absorbance around 700 nm throughout labeled cells. The absorbance 
spectra of nanorods-labeled cells is broadened with the full width at half maximum of 150 
± 7.6 nm compared to 107 ± 4.6 nm for conjugated nanorods in suspension. In addition, 
the T-to-L peak ratio increases by 52 ± 21.31 % relative to isolated nanorods. These optical 
changes can be attributed to EGF receptor mediated aggregation of nanorods. The same 
effect has been observed and thoroughly characterized by our group in the case of EGFR 
targeted spherical plasmonic nanoparticles. [158, 179, 222] 
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It is of interest to note that there is a perception of an increased absorption at cellular 
boundaries in hyperspectral transmittance images (Figure 2.8). This effect is due to light 
diffraction at the interface between cells and the surrounding medium. However, these 
boundary regions in control samples do not exhibit spectral signatures of gold nanorods. 
EGFR-positive A431 cells labeled with anti-EGFR nanorods exhibit strong contrast 
in photoacoustic imaging (Figure 2.10).  Multi wavelength photoacoustic imaging was 
used to obtain spectral characteristics of the labeled cell.  The intensity of the photoacoustic 
signal decreases as a function of wavelength in the 700-800 nm wavelength region; this 
behavior is in good agreement with extinction spectra of the labeled cells (Figure 2.8, 
second row, and Figure 2.10). Note that gold nanorods with extinction maximum at 700 
nm were used in these imaging experiments. As expected, the unlabeled A431 cells did not 
produce any photoacoustic signal. 
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Figure 2.10 Combined ultrasound (US) and photoacoustic (PA) images of tissue-
mimicking cell phantoms.  The phantom on the left consists of A431 cells 
labeled with anti-EGFR gold nanorods and the phantom on the right has 
unlabeled A431 cells. The plot at the bottom shows PA signal intensity 







Directional conjugation involves obtaining a high level of control over an 
orientation of a biomolecule on nanoparticle surface. Orientation is particularly important 
in the conjugation of antibodies to the particle surface as many potential orientations of the 
antibody lead to a loss of antibody binding function, but in general, orientation is also quite 
important for other proteins and molecules.  Directional conjugation can be accomplished 
for molecules that have uniquely accessible functional groups.  In the case of antibodies, 
one such functional group is the carbohydrate moiety located on the heavy chain of most 
antibodies. It was previously demonstrated that periodate-mediated oxidation of the 
carbohydrate group located on the Fc- region of an antibody to an aldehyde can be used for 
oriented conjugation of monoclonal antibodies to an immunopurification matrix containing 
hydrazide functional groups; the resulting matrix yielded the antigen-binding activity close 
to the theoretical value of 2 moles of bound antigens per one mole of a conjugated antibody. 
[211] In this study, a heterofunctional linker with hydrazide and dithiol groups on opposing 
ends of the molecule was used to achieve directional conjugation of antibodies to gold 
nanorods. The hydrazide moiety interacts with the aldehyde on the antibody and the dithiol 
enables conjugation directly to the gold surface.[210]   It is important to note that linkers 
with two adjacent sulfhydryl groups such as thioctic acid provide greater stability as 
compared to a single sulfhydryl group.[217] It has been shown that molecules conjugated 
using single sulfhydryl-containing linkers can be replaced in biological environment by an 
excess of naturally present sulfhydryl-containing biomolecules such as glutathione.[194] 
Previously published methods of synthesis of gold nanorod bioconjugates have 
several downsides including lower in vivo stability of bioconjugates produced by 
electrostatic interactions, cytotoxicity due to presence of CTAB in final nanorods 
conjugates and lack of control over antibody orientation during conjugation.  In addition, 
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most literature reports provide insufficient characterization of prepared conjugates that 
renders assessment of the quality of nanorod conjugate difficult. 
Important information pertaining to the aggregation state and stability of nanorod 
conjugates can be obtained from nanorods extinction spectra before and after conjugation. 
For example, percentage change in the transverse to longitudinal (T-to-L) peak ratio is one 
spectral parameter that can be used in evaluation and comparison of nanorod conjugation 
approaches; other parameters include spectral shift and full-width at half maximum of the 
longitudinal peak. In addition, zeta potential measurements can provide insight into 
changes of surface composition during conjugation reaction steps.  Unfortunately, most 
previously published reports do not include analyses of nanorod extinction spectra before 
and after conjugation with antibodies. The importance of this characterization can be 
illustrated using an example from a recently published conjugation approach where 
bioconjugated nanorods were prepared by, first, replacing the CTAB layer with 11-
mercapto undecanoic acid (MUDA) and then attaching antibody fragments through 
primary amino groups to the carboxylic acid groups of MUDA using EDC chemistry. [88] 
Nanorods with geometrical aspect ratios 2.3 and 3.5 showed approximately 64.7% and 
23.5% increase in the T-to-L peak ratio after CTAB replacement with MUDA, 
respectively, as calculated from the published spectra. These changes indicate potential 
aggregation of nanorods during the conjugation procedure. In contrast, molecular-specific 
nanorods synthesized using the technique reported here undergo increase in the mean value 
of T-to-L peak ratio of less than 9 % (Table 2). In addition, there are no changes in full-
width at half maximum of the longitudinal peak during conjugation procedure or after 
antibody conjugation.  
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2.5 SUMMARY 
In this study, we have developed a robust conjugation technique for reproducible 
synthesis of molecular-specific gold nanorods and have fully characterized conjugates 
using zeta potential, extinction spectra, electron microscopy and hyperspectral optical 
imaging. Furthermore, the nanorod bioconjugates were prepared by attaching the Fc 
portion of antibodies to the nanorod surface that has two important advantages: first, 
directional attachment of antibodies through non-binding Fc moieties provides maximum 
possible binding efficiency of the conjugates; second, since the Fc moieties in the 
conjugates are oriented towards nanorod surface, they are not available for interaction with 
Fc receptors that are present in some human cells including macrophages, providing longer 
residence time and diminishing potential immunogenicity during in vivo applications. 
Molecular-specific gold nanorods synthetized here could be used to image cancer cells 
using optical and photoacoustic imaging. Additionally, we observed characteristic changes 
in optical spectra of molecular targeted nanorods after their uptake by cancer cells; the 
observed spectral signatures can be explored for sensitive detection of interactions between 





Chapter 3: Near-IR Contrast Agents for Immune Cell Tracking‡ 
3.1 INTRODUCTION 
Tracking of immune cells is essential to understand the regulatory role of immune 
cells in pathological conditions such as cancer and cardiovascular diseases[223] that can 
lead to development of novel therapeutic approaches. [224, 225] Moreover, using immune 
cells as transport vehicles for imaging and therapeutic agents can facilitate imaging and 
treatment of cancer cells in vasculature inaccessible areas. Indeed, one of major barriers in 
cancer treatment is inaccessibility of avascular necrotic core of a tumor by traditional 
drugs.  Cancer cells from these hypoxic regions can survive therapy and migrate to 
secondary sites causing cancer metastasis.[226, 227] Immune cells can penetrate the tumor 
necrotic core by following chemokines released by cancer cells that can be used as a 
strategy to deliver a therapeutic payload.[228, 229] Optimization of these new approaches 
to treatment of cancer and other diseases requires development of sensitive imaging 
methods for in vivo tracking of immune cells.  
A direct approach to immune cell tracking is to load cells with contrast agents that 
are suitable for in vivo imaging. Recently, we have demonstrated that loading gold 
nanoparticles into endosomal compartments of stem cells does not alter cellular functions 
including cell viability and differentiation. [230] Furthermore, we have demonstrated that 
stem cells labeled with gold nanoparticles can be tracked in vivo using combined 
photoacoustic (PA) and ultrasound (US) imaging with penetration depth of several 
centimeters.[231] In PA imaging, the tissue is irradiated with nanosecond pulses of low 
energy laser light. Then, through the processes of optical absorption followed by thermal 
                                                 
‡ Adapted with permission from P. P. Joshi, S. J. Yoon, Y.-S. Chen, S. Y. Emelianov, K.V. Sokolov 
Biomed. Opt. Express, 2013, 4(11), 2609-18. Copyright 2013 The Optical Society. Contribution of the 
coauthors – S. J. Yoon performed photoacoustic imaging of the phantom, Y.-S. Chen helped in optimizing 
silica coating procedure of the nanorods, S.Y. Emelianov supervised imaging part of the paper, K. V. 
Sokolov provided overall supervision of the research. 
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expansion, broadband acoustic waves are generated within the irradiated volume. Using an 
ultrasound detector, these waves can be detected and spatially resolved to provide an 
image. Furthermore, the PA imaging can be augmented by US imaging – these systems are 
complementary since both PA and US imaging systems can utilize the same ultrasound 
sensor and associated receiver electronics.[92, 232, 233] 
Gold nanoparticles, including nanospheres,[63, 64, 158, 166, 181, 234-236]  
nanoshells,[66-69] nanocages,[17, 70-72] and nanorods[20, 74-77, 89, 115, 217, 237] are 
of increasing interest to biomedical engineers due to their biocompatibility, facile surface 
modification and high optical cross sections that can provide strong signal in imaging 
modalities based on optical contrast. The optical properties of gold nanoparticles can be 
modulated by changing their size and shape. For example, plasmon resonance of gold 
nanorods is easily tuned in the red to near infrared (NIR) spectral region by changing their 
aspect ratio,[78]  facilitating simultaneous imaging of multiple biomarkers. [76, 88] Strong 
NIR extinction cross-sections of nanorods have been used for two-photon luminescence 
[74, 89] and photoacoustic [90, 91, 92 , 238] imaging of thick biological samples as well 
as for photothermal destruction of cancer cells. [93-95, 239] Thus, anisotropic gold 
nanorods provide a convenient combination of properties for biomedical applications 
including the possibility of cell tracking using PA imaging.[85-87] However, the optical 
absorbance spectra of gold nanorods broaden when they interact with live cells.[115] This 
effect is due to plasmon resonance coupling of closely spaced nanoparticles upon cellular 
uptake and it diminishes the ability to simultaneously image multiple cell populations 
labeled with different nanorods. In addition, recent reports showed that cells more readily 
uptake spherical nanoparticles as compared to rod-shaped particles.[240]  As spherical 
nanoparticles do not have the desired near infrared absorption necessary for in vivo 
imaging, increasing cellular uptake of nanorods is desirable.  
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Here we synthetized silica-coated gold nanorods to address challenges associated 
with the use of rod-shaped gold nanoparticles in cell tracking. Silica coating changes shape 
of the gold nanorods from cylindrical to spheroidal. We demonstrated that the silica-shell 
reduces plasmon resonance coupling between nanorods upon uptake by cells and, thus, can 
facilitate multiplex imaging using nanorods. In addition, the silica shell was doped with 
fluorescent dyes to enable multimodal imaging with fluorescence and PA imaging 
modalities. This combination enables in-depth in vivo imaging of labeled cells using 
photoacoustics followed by high-resolution ex vivo fluorescence imaging for validation and 
detailed characterization of in vivo imaging data. 
 
3.2 RESEARCH APPROACH 
3.2.1 Materials and Methods 
 
Chemicals: AgNO3 (Acros Organics, 41936), HAuCl4 (Sigma, 520918), CTAB (Amresco, 
0833), ascorbic acid (Acros Organics, 401471000), NaBH4 (Fisher, S678), methoxy-PEG-
thiol (5 KDa, Creative PEGworks, PLS-605), Rhodamine B isothiocyanate (Aldrich, 
283924), [3-(2-Aminoethylamino)propyl]trimethoxysilane (AEAPTMS, Aldrich, 
104884), tetraethylorthosilicate (TEOS, Aldrich, 333859), ammonium hydroxide (NH4OH, 
Fisher, A669S), Oxazine 725 (Exciton, 07250),  Polystyrene sulfonate Na salt (18 KDa, 
Polysciences, 16250), Poly(allylamine hydrochloride) (15 KDa, Aldrich, 283215), 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 




Synthesis of PEG-coated gold nanorods (mPEG-NRs): Gold nanorods (NRs) were 
synthesized by seed-mediated growth mechanism using the previously published protocol 
[202]. As-prepared nanorods were washed twice in water by centrifugation at 18000g for 
45 minutes. The final NRs pellet was dispersed in water and stored at room temperature at 
optical density (OD) of 15. Before silica-coating, the cetyl trimethyl ammonium bromide  
(CTAB) layers on NRs were replaced with methoxy-PEG-thiol (mPEG-SH). One milliliter 
of  1 mg/mL mPEG-SH (5kDa) in water was mixed with 1 mL of CTAB-NRs (OD 15) and 
sonicated using a water bath sonicator (Branson 1510R-MT) for 1 minute at room 
temperature. After sonication, the NRs were stirred overnight in the presence of mPEG-
SH to complete replacement of CTAB with mPEG-SH. Free CTAB and mPEG-SH 
molecules were removed by centrifugation through 100kDa centrifugal filters at 2500g for 
15 minutes. Then, the NRs were washed one more time in water to remove any residual 
free mPEG-SH and CTAB. mPEG-NRs were dispersed in 1 mL water and stored at room 
temperature.  
 
Synthesis of silica-coated gold nanorods: We used two approaches to synthesize 
fluorescent silica-coated gold nanorods: 1) encapsulation of a fluorescent dye within silica 
matrix, and 2) covalent attachment of a fluorescent dye to the silica matrix (Figure 3.1). 
Silica shell of a controlled thickness was deposited on PEG-coated nanorods using a 
modified Stöber method[241]. One milliliter of mPEG-NRs (OD 15) was mixed with 1.5 
mL of isopropanol. The solution was continuously stirred while adding 0.6 mL of 3 vol % 
tetraethylorthosilicate (TEOS) and 0.625 mL of 3.84 vol % ammonium hydroxide 
(NH4OH). To the reaction mixture, 40 µL of fluorescent dye, Oxazine 725, solution (11.5 
mg/mL) was directly added to synthesize Oxazine-doped silica-coated nanorods 
(OxSilicaNRs)[242]. Rhodamine (Rh) dye-doped silica-coated nanorods (RhSilicaNRs) 
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were synthesized by first covalently attaching Rh isothiocyanate dye to [3-(2-
Aminoethylamino)propyl]trimethoxysilane (AEAPTMS)[243]. Briefly, 15 µL of 
AEAPTMS was stirred with 10 mg Rhodamine B isothiocyanate in 2.5 mL of anhydrous 
isopropanol (IPA) for 48 hours under nitrogen. This solution was five times diluted in 
anhydrous IPA before adding to the nanorods. One milliliter of mPEG-NRs (OD 15) was 
mixed with 1.5 mL of isopropanol. The solution was continuously stirred while adding 0.6 
mL of 3 vol % TEOS and 0.625 mL of 3.84 vol % NH4OH. After 30 minutes, four aliquots 
(12.5 µL each) of the diluted Rhodamine-AEAPTMS solution were added to the reaction 
mixture (TEOS:Rh-AEAPTMS molar ratio 1080:1). The aliquots were separated by 10 
minutes time interval. After 2 hours of stirring at room temperature, the silica-coated 
nanorods were collected by centrifugation at 700g for 15 minutes using 100 kDa MWCO 




Figure 3.1 Schematic of two approaches used to synthesize fluorescent silica-coated 
nanorods. 
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Synthesis of polymer-coated nanorods: Polymer-coated nanorods were synthesized by 
mixing 1 mL of CTAB-coated gold nanorods (OD 10) with 1 mL of polystyrene sulfonate 
(PSS) solution (10 mg PSS per 1 mL of 1 mM NaCl) [89, 220]. The solution was kept on 
a shaker for 30 minutes and then centrifuged at 18000g for 15 minutes. The nanorods 
containing pellet was redispersed in 1 mL of 1 mM NaCl solution and was mixed with 1 
mL of PSS solution. The solution was placed on a shaker for 30 minutes and then 
centrifuged to collect the nanorods coated with PSS. The PSS-nanorods were coated with 
Poly(allylamine hydrochloride) (PAH) using the same procedure. PSS-nanorods pellet was 
dispersed in a 1 mL NaCl solution (1 mM) and mixed with 1 mL of PAH solution (10 mg 
PAH per mL of 1 mM NaCl). After 30 minutes of shaking, the nanorods pellet was 
collected using centrifugation and dispersed in a salt solution. The PAH coating procedure 
was repeated once more to obtain PAH-PSS-nanorods. The final nanorods pellet was 
dispersed in 1 mM NaCl solution. 
 
Cell viability study: The viability test of monocyte/macrophage (RAW 264.7) cells was 
performed after incubating the cells with OXSilicaNRs or RhSilicaNRs at a given 
concentration in phenol-free DMEM cell culture media for 18 hours at 37C. As the 
nanorods-loaded cells need to be viable for a long period for successful cell tracking 
application, extended cell viability tests were performed by culturing cells in regular cell 
culture media for an additional 24 to 48 hours after incubation of cells with silica-coated 
nanorods.  To perform cell viability study, the cells were washed once with PBS and a 
background absorbance was measured at 490 nm using BioTek Synergy HT UV-Vis 
spectrophotometer. Then MTS reagent (mixture of MTS and PMS prepared in phenol free 
cell culture media) was added to the cells. After 3 hours of incubation with MTS reagent 
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solution, absorbance at 490 nm was measured again. Background absorbance was 
subtracted in order to determine the number of metabolically active live cells in a sample.  
Two mouse-macrophage cell lines, RAW 264.7 and P388D1, were used for cell 
labeling and characterization throughout this study. While RAW 264.7 cells are highly 
phagocytic macrophage cells, P388D1 cells have an inferior phagocytic activity [244, 245]. 
In order to achieve comparable loading of nanorods in both cell lines, we used higher 
dosage of nanorods for P388D1 cells (1x107 NRs/cell) compared to RAW 264.7 cells 
(7x104 NRs/cell). The cells were incubated with nanorods for 18 hours at 37C in cell 
culture media.  Labeled cells were washed with cell culture media to remove any unbound 
nanorods and re-suspended in phenol free media to measure absorbance. Absorbance 
spectra of unlabeled cells were subtracted from the spectra of nanorod-loaded cells to 
obtain the contribution from nanorods. Before the measurements, cells were counted using 
a standard hemocytometer in the presence of trypan blue. Trypan blue is a vital stain that 
selectively colors dead and lysed cells. More than 95% of cells were vital during the 
absorption measurements based on trypan blue staining.     
 
Tissue mimicking phantom preparation: Gelatin based tissue-mimicking phantoms with 
cell inclusions were fabricated for combined photoacoustic and ultrasound imaging. To 
simulate tissue background, 8wt% gelatin solution with 0.2wt% of 15 µm silica particles 
was used to prepare the base and the top layers which encapsulated the cell inclusions. 
Suspensions of P388D1 cells only and P388D1 cells loaded with RhSilicaNRs were mixed 
with the same volume of 16wt% gelatin solution at 37oC. Specifically, five inclusions of 
P388D1 cells loaded with RhSilicaNRs were prepared with cells concentrations 5 × 106, 
2.5 × 106, 1.25 × 106, 2.5 × 105, and 1.25 × 105 cells/mL. For the inclusion with only cells, 
5 × 106 cells/mL cell concentration was used. The phantoms with only silica-coated 
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nanorods were prepared using the given concentration of nanorods per inclusion. For 
phantom preparation, suspension of silica particles in gelatin at 37oC was poured in a petri 
dish and was cooled down at 4oC. During the cool down step, some silica particles settle 
down resulting in reduced ultrasound contrast in the top part of the phantom. Then, 
suspensions of cells in gelatin were placed on the solidified base layer and were allowed 
cool down. Finally, the top layer of gelatin/silica particles was added to complete the 
phantom. 
 
Animal studies: All animal work performed for this study was approved under IACUC 
protocol AUP-2009-00090. Mice were subcutaneously inoculated with A431 cells and the 
tumor was allowed to grow to about seven millimeter in size. The mice were then imaged 
before the injection of control cells or cells loaded with either gold nanospheres or 
RhSilicaNRs. Noninvasive longitudinal imaging was performed up to 48 hours post-
injection using combined ultrasound and photoacoustic imaging.  
 
Photoacoustic imaging set-up: Photoacoustic imaging of the tissue-mimicking phatom 
was performed using a Vevo® 2100 LAZR imaging system (VisualSonics, Inc., Toronto, 
Canada) and an array ultrasound transducer (LZ250, VisualSonics, Inc.) operating at 20 
MHz center frequency. A  laser beam with 5 ns pulses and 20 Hz repetition rate was 
generated by a tunable OPO laser system pumped by  Nd:YAG laser. The wavelength of 
the laser in the phantom imaging experiment was matched to the peak optical absorption 
wavelength of the silica-coated nanorods, which is 780 nm. The laser beam was delivered 
through an optical fiber bundle integrated with the ultrasound array transducer. A 
mechanical system was used to translate the transducer in steps of 114 μm to allow for 
collecting multiple cross-sectional images of the inclusions using combined US and PA 
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imaging. In order to perform a quantitative photoacoustic signal comparision between each 
inclusion, fluence of the laser was maintained at 10 mJ/cm2, which is below the damage 
threshold for silica-coated nanorods [241]. To compensate the PA signal amplitude for 
laser fluctuations, laser fluence was recorded by the VEVO 2100 LAZR imaging system 
during PA imaging and PA signals were normalized by laser fluence in post-processing. 
PA signal intensity of each inclusion was measured by averaging PA signals from 11 
different cross-sectional images of the inclusion. 
 
3.3 RESULTS AND DISCUSSION 
The RhSilicaNRs and OXSilicaNRs were characterized using TEM and 
fluorescence emission. Transmission electron microscopy shows a uniform silica layer on 
the silica-coated nanorods after both syntheses (Figure 3.2). Fluorescence emission spectra 
of RhSilicaNRs and OXSilicaNRs indicate successful encapsulation of fluorescent dyes in 
the silica-coated nanorods (Figure 3.2). 
 
 
Figure 3.2 Transmission Electron Microscopy of Oxazine silica-coated nanorods 
(OxSilicaNRs) (left) and Rhodamine silica-coated nanorods (RhSilicaNRs) 
(middle), scale bar: 100 nm; fluorescence emission spectra of OxSilicaNRs 





Cellular tracking requires long-term viability of the nanoparticle-loaded cells.  Here 
we used monocyte macrophage cell line (Raw 264.7) to evaluate extended viability of cells 
loaded with  silica-coated flourescent nanorods following an 18 hours incubation (Figure 
3.3). The nanorod-loaded macrophages were grown in fresh cell cuture media for 24 and 
48 hours before testing cell viability. OxSilicaNRs showed no toxicity right after the 
incubation step; however, significant cell death was observed during subsequent cell 
culture (Figure 3.3 (a)). In contrast, RhSilicaNRs did not cause any post-incubation long-
term toxicity (Figure 3.3 (b)). The toxicity of OxSilicaNRs can be attributed to non-
covalent attachment of the Oxazine dye to the silica matrix that may result in leakage of 
the dye within the cells over a long period of time leading to the long-term toxicity. A slight 
decrease in viability of cells loaded with mPEG-NRs after 24 hours culture can be 
attributed to a small amount of residual CTAB molecules which are present after ligand 
exchange with mPEG-SH [115]. Because of the lack of cytotoxicity, RhSilicaNRs were 







Figure 3.3 Viability of mouse monocyte macrophage cell line (Raw 264.7) loaded with 
either OxSilicaNRs (a) or mPEG-NRs and RhSilicaNRs (b) immediately 
after 18 hrs of incubation with nanoparticles and 24 or 48 hours of cell 
culture in fresh media after nanorod-loading. RhilicaNRs show no toxicity 
during extended cell culture of labeled cells, whereas OxSilicaNRs exhibit 
significant cytotoxicity. Statistically different results compared to controls 
using student t-test (p-value < 0.01) are identified by *. 
 
Silica-coated nanorods exhibit negligible changes in the longitudinal peak position 
and the full-width at half-maximum (FWHM) values after uptake by two macrophage cells 
lines - RAW 264.7 and P388D1 (Figure 3.4 (a), (b) and Table 3.1). In contrast, nanorods 
coated using layer-by-layer deposition of polystyrene sulfonate (PSS) and poly(allylamine 
hydrochloride) (PAH) polymers [246] show significant change in the optical absorption 
upon  cellular uptake (Figure 3.4 (c), Table 3.1). Note that RhSilicaNRs, SilicaNRs and 
PAH-PSS-NRs have different longitudinal peak maxima. These results demonstrate that 
silica coating of ca. 30 nm provides sufficient spacing to prevent plasmon resonance 
coupling of nanorods after they are uptaken by live cells.  Since silica-coated gold nanorods 
do not change optical spectra inside cells, we used extinction coefficients of the nanorods 
in suspension to determine nanorod loading of cells. RAW 264.7 and P388D1 cells 
accumulated ca. 104 and 2x104 silica-coated nanorods per cell, respectively.  Cells loaded 
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with RhSilicaNRs can be readily viasualized using fluorescence imaging (Figure 3.5 (e), 
(f)). Negligible  nanorod-specific contrast was observed in the dark-field images of 
RhSilicaNRs-loaded cells due to low sensitivity of our optical microscope to NIR 
logitudinal resonances of the nanorods used in this study (Figure 3.5 (b), (c)). Thus, 
fluorescence imaging provides a convenient way of identifying cells labeled with dye-





Figure 3.4 Extinction spectra of: (a) RhSilicaNRs in suspension and P388D1 cells 
loaded with RhSilicaNRs; (b) SilicaNRs in suspension and RAW 264.7 cells 
loaded with SilicaNRs; (c) polymer-coated nanorods (PAH-PSS-NRs) in 
suspension and RAW 264.7 cells loaded with PAH-PSS-NRs.  Longitudinal 
peak position and extinction spectra of silica-coated nanorods do not 
undergo significant changes after cell uptake in contrast to polymer-coated 











RhSilicaNRs  120  782 
P388D1 cells with RhSilicaNRs 138 15.00% 778 
SilicaNRs    83  704 
RAW 264.7 cells with SilicaNRs 87 4.82% 700 
PAH-PSS-NRs 139  725 
RAW 264.7 cells with PAH-PSS-NRs 222 59.71% 800 
Table 3.1 Characterization of the absorbance spectra of nanorods and cells-loaded 
with nanorods; FMHM – full-width at half maximum. 
 
Previous literature reports have shown good contrast in dark-field imaging of gold 
nanorods with a longitudinal peak in the visible range [247, 248]. It has been also reported 
by us [115] and other groups [93, 199, 249] that cells loaded or labeled with gold nanorods 
coated by a thin layer of organic ligands and targeting biomolecules produce detectable 
contrast in dark-field images as compared to unlabeled cells. We attribute this contrast to 
plasmon resonance coupling between closely spaced nanoparticles in  the cellular 
endosomes that results in an overall increase in scattering in the visible region. In the 
present study, silica coating around nanorods significantly diminishes the effect of plasmon 
resonance coupling as described above and, therefore, silica-coated nanorods do not 





Figure 3.5 Dark-field (a, b, c) and fluorescence (d, e, f) images of RAW 264.7 cells 
alone (a, d), RAW 264.7 cells loaded with RhSilicaNRs (b, e), and P388D1 
cells loaded with RhSilicaNRs (c, f). Scale bar = 50 µm. Images were 
acquired with Leica DM600 upright microscope using 20x 0.5 NA 
objective. Fluorescence imaging was performed using Cy3 filter cube, 
ex/em 555/590 nm.  
 
 
Having successfully loaded cells with the silica-coated nanorods, the next step was 
to evaluate feasibility of sensitive detection of the nanorod-loaded cells  using PA imaging. 
To this end, inclusions containing different concentrations of P388D1 cells loaded with 
RhSilicaNRs were incorporated in the tissue-mimicking phantoms and multiple cross-
sectional PA images of each inclusion were collected at 780 nm wavelength, which 
corresponds to the longitudinal plasmon resonance peak of the nanorods (Figure 3.6). 
Although the same matrix was used to prepare the top and bottom layers of the phantom, 
settlement of silica particles in the bottom layer of the phantom results in a decreased US 
contrast at the boundary between the top and the bottom layers (approximately in the 
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middle of the images on Figure 3.6 (a).  PA signal intenstiy showed linear behaviour as a 
function of concentration of labeled cells (the R2 value for the linear regression fit is 
0.9753). From the linear regression fit in Figure 3.6 (b), we determined that the PA imaging 
can detect ca. 1.25 x 106 cells evenly dispersed in a 1 cm3 volume. After taking into account 
the imaging kernel size of the photoacoustic system (approximately 160 μm x 110 μm x 
220 μm), we calculated that PA imaging could detect as few as five nanorod-loaded cells 
per imaging kernel. Because the current threshold for clinical detection is about 109 cells 
growing as a single mass as depicted in the Figure 3.7, the enhancement in the detection 





Figure 3.6 Photoacoustic images of tissue-mimicking phantoms prepared with different 
concentrations of P388D1 cells loaded with Rh-Silica-NRs (a). Each image 
covers a 6.3 x 8.8 mm field of view. Dependence of the PA signal 
amplitudes on the concentration of nanorod-loaded cells at 780 nm 
excitation wavelength (b); the top horizontal axis shows a number of cells 
per imaging kernel of the photoacoustic system used. The solid blue line 
represents the linear regression fit of the data and the black line shows the 





Figure 3.7 Gompertzian growth curve of a solid tumor and its relationship to cancer 
detection and imaging. Number of malignant cells (ordinate) as a function of 
time (abscissa). The transition from first lag to log phase of growth, 
associated with the transition from diffusion-limited nutrition to 
neovascularization, is labeled “angiogenic switch.” Remission is shown as 
the uncertainty of cell number ranging from zero to the current clinical 
threshold for cancer detection (approximately 109 cells growing as a single 
mass). Reprinted with permission from ref [14]. 
 
One of the concerns while using cells labeled with exogenous contrast agents as 
described in this study is the possibility of imaging the label –gold nanorods – instead of 
tracking the cells labeled with gold nanorods. To this end, we have prepared tissue-
mimicking phantoms with different concentrations of RhSilicaNRs to evaluate the 
sensitivity of detecting nanorods by themselves (Figure 3.8). We found that even with very 
high concentrations of RhSilicaNRs (1013 NRs/mL), we cannot obtain much contrast using 
PA imaging. This concentration corresponds to 2x107 RhSilicaNRs per imaging kernel 
compared to the detection limit of 105 RhSilicaNRs when they are within the cells. The 
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effect of PA signal enahncement upon aggregation of silica-coated nanoparticles is also 
previously observed by our group.[250] Clearly, we have not only achieved high sensitivity 
for cell tracking, but also significantly reduced the potential background signal arising from 





Figure 3.8 Photoacoustic images of tissue-mimicking phantoms prepared with different 
concentrations of RhSilicaNRs. Imaging was performed at the longitudinal 
peak wavelength of nanorods. 
 
An exploratory in vivo study was performed to image infiltration of gold 
nanoparticles-loaded macrophages in a solid tumor using photoacoustic imaging. First, 
RAW264.7 cells loaded with gold nanospheres were injected in a tumor-bearing mouse.  
The tumor was imaged before injection and after 6 or 24 hours of administration of gold 
nanospheres-loaded RAW264.7 cells. The distribution of  hemoglobin, deoxy hemoglobin 
and nanoparticles was obtained as shown in Figure 3.9 using spectroscopic PA image 
analysis considering the individual spectra of the absorbers (Figure 3.9, d). As the 
extinction spectra of the cells loaded with spherical gold nanoparticles was similar to the 
deoxy hemoglobin spectra, the spectroscopic analysis could not distinguish nanoparticle 





Figure 3.9 In vivo longitudinal spectroscopic photoacoustic imaging of A431 tumor in 
mouse before (a) injection of RAW267.4 cells loaded with gold nanospheres 
and after 6 hours (b) or 24 hours (c) of injection of gold nanospheres-loaded 
RAW267.4 cells. Images in each panel includes ultrasound image (gray), 
photoacoustic image (orange), distribution of hemoglobin (red), deoxy 
hemoglobin (blue) and gold nanospheres-loaded RAW264.7 cells from 
spectroscopic PA imaging. Normalized absorption spectra (d) of the three 
absorbers used in spectroscopic PA image analysis. 
 
 
We then performed the similar study with RhSilicaNRs-loaded RAW264.7 cells 
injected in tumor-bearing mice. The normalized spectra for the three absorbers differed 
significantly as seen in Figure 3.10. As a result, when only cells without any nanorods were 
administered, the spectroscopic analysis of PA images did not show any contrast related to 
the nanorods (Figure 3.11, a). However, when RhSilicaNRs-loaded RAW264.7 cells were 
injected, the signal correlated to gold nanorods increased with time (Figure 3.11, b).  This 
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preliminary study revealed the feasibility of in vivo tracking of cells labeled with silica-
coated gold nanorods using spectroscopic photoacoustic imaging. For this study, we 
observed significant enhancement of signal related to gold nanorods only for one out of 
three mice imaged. For the future studies, enhancing the tumor-homing properties of the 
immune cells before injecting them in mice may increase the accumulation of labeled cells 
within the tumor. Additionally, an in vitro tumor model of spheroid can greatly facilitate 
understanding of immune cells’ infiltration within tumor.[251] Three-dimensional 
spheroids of cancer cells can be readily prepared and grown to an appropriate size to mimic 





Figure 3.10 Normalized absorption spectra (red-color shaded portion) used for 






Figure 3.11 In vivo longitudinal spectroscopic photoacoustic imaging of A431 tumor in 
mice after injection of either RAW264.7 cells only (a) or RAW264.7 cells 






In summary, we systematically addressed challenges associated with applications 
of gold nanorods in cell imaging. First, we demonstrated long-term biocompatibility of 
fluorescent silica-coated nanorods for cell tracking experiments. Then, we showed that 
silica-coated nanorods do not alter optical properties upon cellular uptake that can facilitate 
multiplex imaging and tracking of various cell populations. Furthermore, our previous 
studies demonstrated that silica coating increases stability [241] and signal strength [253] 
of gold nanorods in PA imaging. The combination of these properties that are afforded by 
silica coating results in the detection limit of just few labeled cells in tissue mimicking 
phantoms. These promising results provide the foundation for applications of silica-coated 
gold nanorods and PA imaging in tracking of cells in studies ranging from the mechanistic 
understanding of immune responses in cancer and cardiovascular diseases to the cell 
mediated delivery of therapy. 
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Chapter 4: Biodistribution and Clearance of Near-IR Contrast Agents 
 
4.1 INTRODUCTION 
The clinical use of any contrast or therapeutic agent necessitates thorough 
investigation about its biodistribution and clearance. An ideal contrast agent would have 
sufficient blood circulation time to allow accumulation in the diseased area, and then would 
be able to excrete from the body within a reasonable timeframe to avoid long-term 
accumulation and adverse side effects. The abundant literature on in vivo circulation and 
clearance of nanoparticles provides insight into the size and surface chemistry of 
nanoparticles that can be optimal for enough circulation time in blood facilitating imaging 
and therapy. [126-129, 132] Renal excretion of nanoparticles with a size less than 5-nm is 
efficient; however, larger nanoparticles that cannot degrade in a biological environment 
become sequestered in the mononuclear phagocytic system (MPS) organs, mostly the liver 
and spleen.[130, 131, 254, 255] Quick excretion of small nanoparticles, however, does not 
allow enough circulation time in the blood to facilitate accumulation in the diseased site. 
The contrast agents for cancer imaging need to have enough circulation time in the blood 
to accumulate at the tumor site via enhanced permeability and retention (EPR) effect. 
Although, larger nanoparticles with optimized surface stay longer in blood circulation, but 
they also accumulate in MPS organs.[254] Clinically acceptable contrast agents should 
satisfy both criteria: 1) long enough blood residence time for accumulation in the diseased 
site and 2) clearance from the body within a reasonable time after imaging. 
Gold nanorods optimized earlier in this dissertation are excellent near infrared 
contrast agents suitable for in vitro, ex vivo, or preclinical research using small animals. 
Prolonged accumulation of gold nanorods in the liver and spleen, however, renders them 
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poor candidates for clinical applications. [132, 256, 257]  Although their bigger size 
imparts sufficient blood residence time, efficient renal clearance requires nanoparticles 
with smaller size (5-nm or less).[130] Recently, biodegradable nanoclusters from small 
gold nanoparticles (5-nm) and block-co-polymer of polylactic acid (PLA) and polyethylene 
glycol (PEG), PLA (1k)-PEG(10k)-PLA(1k) are synthesized. By varying polymer/Au 
ratio, the gold nanoclusters of various size were formed. The equilibrium size the 
nanoclusters was governed by the balance of short-ranged attractive forces with longer-
ranged electrostatic repulsive forces between the charges particles.[138] Although the 
primary gold nanoparticles used for the synthesis of the nanoclusters possess overall 
negative charge, they have shown to resist protein absorbance even in undiluted serum. 
[258] Moreover, the biodegradable nanoclusters can be degraded to their original size in 
acidic environments of the cellular endosomes,[137] and the degraded nanoparticle also 
retain their protein repelling abilities. As the degraded nanoparticles do not absorb any 
proteins and retain their sub 5-nm size ideal for renal excretion, the biodegradable gold 
nanoclusters make perfect candidate for clinical applications having optimum blood-
residence time and good renal clearance.  
 Apart from the physical characteristics suitable for in vivo application, these 
clusters also have a strong near infrared absorption necessary for in vivo imaging. [139] 
Because the biodegradable clusters possess all the characteristics of an ideal clinical 
contrast agent, this study evaluates these promising nanoparticles in terms of their 
biodistribution and clearance using in vitro as well as in vivo studies. 
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4.2 RESEARCH APPROACH 
4.2.1 Materials and Methods 
Synthesis of biodegradable clusters: The biodegradable nanoclusters were synthesized 
with little modification of the published procedure. [137, 138] Briefly, citrate-capped gold 
nanospheres with a size less than 5-nm were coated with lysine by adding 20 µL of freshly 
prepared aqueous solution of 5% w/v (50 mg/mL) lysine to a 1.2 mL of citrate-capped 
nanospheres (3 mg Au/mL) solution. Nanoclusters were formed by adding aqueous 
solution of PLA (poly-lactic acid)(1k)-b-PEG (polyethylene glycol)(10k)-b-PLA(1k) 
polymer to the nanospheres’ dispersion and evaporating 50% of the solution under air flow 
for 40 min. The nanoclusters were diluted to 0.05 mg Au/mL in water and filter sterilized 
using 0.45 µm filter before concentrating to 2.7 mg Au/mL using centrifugation. 
PEGylated nanoclusters were prepared by adding 5-kDa mPEG-SH to the diluted clusters 
and letting them react for 20-minutes at room temperature before filter sterilization and 
centrifugation. 
 
Animal studies: All animal studies performed for this chapter were approved under 
IACUC protocol AUP-2012-00020. The in vivo clearance study was conducted with an 
intravenous injection of normal Balb/c female mice (2-4 months old) with 200 µL of gold 
nanoclusters solution (2 mg Au/mL). Before injection, 2.7 mg Au/mL nanoclusters were 
diluted to 2 mg/mL using phenol-free DMEM media with serum. After the injection of the 
nanoclusters, each mouse was housed in a separate metabolic cage for collection of urine 
and feces. The mice were sacrificed after 1, 7, or 14 days. Immediately after euthanasia, 
blood was collected to perform an alanine aminotransferase (ALT) test using a kit 
purchased from Abcam (ab105134). Five mice at each time point were injected with gold 
nanoclusters. For each time point, one mouse was injected with diluted DMEM media (the 
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same dilution used for the nanoclusters) to use as a control. Various organs including liver, 
spleen, and kidneys were collected, digested using microwave digestion system in 
concentrated acid solution (10 mL conc. HNO3 + 1 mL conc. HCl) and analyzed for their 
accumulation of gold using ICP-MS. A portion of these tissues was fixed in formalin for 
histopathological analysis. 
 
In vitro Clearance Study: Clearance of biodegradable nanoclusters from mouse 
macrophage cells (J774A.1, ATCC) and mouse hepatic sinusoidal endothelial cells 
(T0102, Applied Biological Materials, Inc., referred as LSECs in this report) over a period 
of one week was performed. Phenol free DMEM with 1% penicillin-streptomycin 
supplemented with either 10% FBS (for J774A.1 cells) or 5% FBS (for LSECs) was used 
for this study. Cells were plated (1000 cells per cm2) in tissue culture flasks/dishes and 
allowed to adhere overnight. Gold nanoclusters were preincubated in fetal bovine serum 
(FBS, 50%) for 2 hours before exposing to cells. Cells were incubated with nanoclusters 
(0.2 mg Au per mL of phenol free DMEM media with 1% penicillin-streptomycin and 7% 
FBS) for 4 hours. At the end of incubation time, the nanoclusters were removed and the 
cells were washed with PBS (without calcium and magnesium) twice before a fresh cell 
culture media was added and they were allowed to grow for 0, 1, 4 or 7 days. The media 
was changed once on day 4. All of the experiments were done at least in triplicates. At a 
specified time, the cells were harvested (LSECs by trypsin and J774A.1 by scrapping), 
counted, and their extinction measured using UV-Vis. Cells were recovered from UV-Vis 
measurement and analyzed with ICP-MS for gold quantification after digestion in 
concentrated aqua regia (3:1 HCl:HNO3 by volume). The cell viability was compared to 
control cells using Calcein AM staining of live cells.  
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4.3 RESULTS AND DISCUSSION 
One of the major concerns regarding the use of metallic contrast agents in the clinic 
is their sequestration in the MPS organs. The inability of the contrast agent to be cleared 
from the body after imaging can cause long-term toxicity due to prolonged accumulation. 
[126] Nanoparticle size, along with surface functionality, plays an important role in renal 
clearance. Nanoparticles less than 5-nm can be effectively cleared though the kidneys [130, 
255] and the larger nanoparticles accumulate in the liver and spleen with no indication of 
clearance over time. [132, 256]  However, the downside of quick clearance is that there is 
not enough time for systemic circulation to effectively label the organs of interest and 
facilitate imaging. Furthermore, gold nanoparticles less than 5-nm do not have near-IR 
absorbance and hence are not suitable for in vivo imaging.  
The perfect clinical contrast agent would have good near-IR absorbance with size 
and surface properties ensuring long enough circulation to serve imaging needs and achieve 
clearance from the body within a reasonable time post-imaging. In this study, we have 
evaluated biodegradable nanoclusters synthesized from 5-nm gold nanospheres and 
biodegradable polymer. Nanoclusters’ size is tunable to achieve necessary circulation time, 
however the biodegradable polymer degrades within the acidic endosomal compartments 
of cells and results in smaller primary particles that can potentially be excreted by the 
kidneys.[138] The biodegradable clusters are synthesized using poly-lactic-acid and poly-
ethylene glycol co-polymer and less than 5-nm diameter spherical gold nanoparticles. The 
primary particles that form after degradation of the clusters do not absorb serum protein 
even in 100% serum and thereby keeping their size small enough for renal clearance.[258] 
Although the individual primary nanoparticles do not have any near-IR absorbance, the 
biodegradable clusters have high near-IR extinction due to plasmon coupling between the 
primary nanospheres (Figure 4.1). Here we evaluate biodistribution and clearance of 
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biodegradable nanoclusters in mice to reveal the feasibility of using these contrast agents 
in the clinic. The excretion characteristics of these nanoparticles from major cells types in 
the RES system is established using an in vitro cell clearance study in hopes of developing 
a cell-based screening model to predict the outcome of in vivo excretion of novel 
nanoparticle formulations.  
Biodegradable nanoclusters with optical and physical characteristics shown in 
Figure 4.1 were used in this study. The nanoclusters with 20 nm size showed high near-IR 





Figure 4.1 UV-Vis extinction spectra (a) and dynamic light scattering (DLS) based size 
distribution (b), and TEM images (c) of gold nanoclusters. (Nanoclusters are 
synthesized and characterized by Prof. Keith Johnston’s lab). Gold 
nanoclusters of size 20 nm show good near-IR extinction. 
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The animal study design for this project is depicted in Figure 4.2. Normal Balb/C 
mice were injected with nanoclusters, PEGylated nanoclusters or just a diluted media via 
tail vein. The mice were then housed in the metabolic cages to facilitate collection of feces 
and urine (Figure 4.3). After a specific time, the mice were euthanized and the blood and 
organs were harvested for further analysis. 
 
Figure 4.2 Flow chart of biodistribution and clearance study of biodegradable 




Figure 4.3 Visualization figure for biodistribution and clearance study performed for 
this project 
The mice were sacrificed on 1, 7, or 14-days post injection of nanoclusters; 
biodistribution of gold in MPS organs was determined using ICP-MS (Figure 4.4). After 
one day of systemic circulation, no gold was detected in the blood with the majority of the 
injected dose having accumulated in the liver. Interestingly, only within the first week, 
25% of the accumulated gold per gram of liver was cleared (statistically significant 
difference). The significant clearance of gold only within one-week period is encouraging, 
as the prior study done using higher dosage (1.2 mg Au per mice) of gold nanoclusters (size 
40 nm) did not show any statistically significant clearance of gold from liver until 3-month 
time point. [259] The slow clearance observed for that study may be due to using very high 
dosage of gold that may have overwhelmed the clearance system. Fast clearance of gold 
nanoclusters is very promising, however, the continued clearance of gold was not observed 
after the first week. Gold accumulation in the liver at the two-week time point was 
statistically the same as at the one-week time point. Initial clearance of nanoclusters 
followed by a stagnant phase lead to an interesting revelation about the complex biological 




Figure 4.4 Biodistribution of gold nanoclusters in mice with respect to time. Number 
given by n represents the number of animals used per time point. 
Statistically different results compared to day 1 based on student t-test (p-
value < 0.05) are identified by *. 
 
The macrophages of the liver and spleen are considered to be the main role players 
in clearing systemically injected foreign materials. [260] Here we processed the liver fixed 
in formalin with a silver stain to highlight gold nanoparticles and with a F4/80 stain to label 
macrophages. Figure 4.5 shows the liver images of mice after one day of nanoclusters’ 
injection. In the microphage-stained image, the gold nanoparticles are also visible due to a 
high contrast in bright field imaging. Although nanoparticles were associated with 
macrophages (highlighted by the black arrow), a considerable amount of nanoparticles 
were also present in the non-parenchymal non-macrophage cells (denoted by red stars). 
Apart from the macrophage cells, the main scavenger cell type of the liver, multiple 
research groups highlight the role of the liver sinusoidal endothelial cells (LSECs) in 
clearing pathogens and toxins. [261-265] The presence of gold nanoparticles in non-





Figure 4.5 Silver stain (left) and mouse macrophage F4/80 stain (right) images of the 
mouse liver after one day of intravenous injection of nanoclusters. Scale bar 
= 4.69 µm. Blue arrows point to peroxisomes in the cells that are stained 
lightly. Black arrows point to the liver macrophages. Nanoparticles in non-
macrophage cells are marked by a red asterisk (*) 
Analysis of silver-stained and F4/80-stained liver images using ImageJ and Matlab 
from mice euthanized on 1, 7 or 14-days after nanoclusters’ injection reveals that the 
percentage of pixels with nanoparticles overlapping with macrophages are small for day 1 
and day 7. However, the overlap of nanoparticles with macrophages increased 4-times 
within the second week after the nanoclusters injection (Figure 4.6). The increase in the 
percentage of nanoparticles overlapping with macrophages during the second week can be 
due to: 1) clearance of nanoparticles from the non-macrophage cells resulting in more 
nanoparticles per image associated with the macrophage cells or 2) transfer of 
nanoparticles from the non-macrophage cells to the macrophages within the second week. 
Because ICP-MS results (Figure 4.4) do not show clearance within second week, the first 
option of net clearance of nanoparticles from the liver would not hold true. However, the 
nanoparticles can be transferred from the other cells to macrophage cells via intercellular 





Figure 4.6 Results from the image analysis of the silver-stained and macrophage 
(F4/80)-stained images of the liver performed using ImageJ and Matlab 
 
Liver sinusoidal endothelial cells (LSECs) clear 90% of the adenovirus from blood 
circulation within minutes. [264] Fast clearance of the small size pathogen from circulation 
can be due to efficient endocytosis by LSECs. Endocytosis observed in LSECs is mainly 
clathrin-dependent, with LSECs having twice as many clathrin-coated pits per unit 
membrane compared to Kupffer cells. [266] Apart from the fast uptake kinetics of LSECs, 
the degradation products of the ligands for scavenger receptors and mannose receptors on 
LSECs appear in circulation within minutes. [265] The recent in vitro study by Detzel, et 
al. reveals that 60-70% of gold nanoparticles are cleared from both the hepatocytes and 
liver sinusoidal endothelial cells within seven days. [267] Alternatively, Kupffer cells show 
a slow clearance of phagocytosed material. [268, 269]  Combining these traits of LSECs 
and Kupffer cells, clearance of gold from the liver during the first week, as observed by 
ICP-MS analysis (Figure 4.4), can be due to the fast clearance from LSECs. An increase 
in the percentage of nanoparticles overlapping with macrophages from histology image 
analysis (Figure 4.6) can be due to the transfer of remaining NPs from LSECs to the 
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macrophages during the second week either by phagocytosis of LSECs containing gold 
NPs by macrophages or by an alternate intercellular transfer mechanism.  
Blood concentration of the liver enzyme – Alanine transaminase (ALT) – normally 
increases during liver damage.[270] For all mice injected with nanoclusters, the ALT 
concentrations were similar to the control mouse, suggesting that the nanoclusters do not 







      
 
       
 
 
Figure 4.7 Concentration of ALT enzyme in the blood of individual mouse at day 1 (a), 
week 1 (b), week 2 (c). Average concentration of ALT enzyme in control 
and nanoclusters-injected mice after different time points (d). Normal level 
of the liver enzyme, ALT, suggests no changes in liver function after 
injection of gold nanoclusters in mice. 
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Combined photoacoustic and ultrasound imaging was performed on the excised 
livers of the control mouse and mice injected with nanoclusters at different time point after 
nanoclusters’ administration (Figure 4.8). Strong PA contrast was observed from livers of 
mice injected with nanoclusters with no significant contrast from the liver of control 
mouse. This observation suggests the feasibility of detecting nanoclusters distribution in 






Figure 4.8 Ultrasound (US) and photoacoustic (PA) images of the excised livers of the 
control mouse and mice after one, seven and fourteen days of gold 
nanoclusters’ injection. PA imaging performed at 700 nm. Each image 
covers 8 x 14 mm field of view.  
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The effect of PEGylation on biodistribution of nanoclusters was studied by 
intravenously injecting PEGylated clusters into mice.  Figure 4.9 shows the distribution of 
NPs in RES organs and blood for mice injected with nanoclusters and PEGylated-
nanoclusters after one day of nanoparticles administration. The distribution of nanoclusters 
with and without PEG changed drastically between the liver and spleen. The spleen took 
up PEGylated nanoclusters about 7-times more compared to regular nanoclusters, with 
consequent decrease in uptake by the liver for the PEGylated nanoclusters. One explanation 
for the difference in biodistribution can be the increased blood residence time of the 
nanoparticles due to PEG-coating, which in turn results in a greater accumulation of 





Figure 4.9 Distribution of nanoclusters and PEGylated nanoclusters in RES organs in 
normal Balb/c mice after one day of intravenously injection. Number 




Clearance of nanoparticles from systemic circulation depends on opsonization of 
the nanoparticles in blood. Although the biodegradable nanoclusters used in this project do 
have some surface coverage of PEG, further PEGylation of nanoclusters increases PEG 
density, changing the kinetics of nanoclusters’ opsonization in blood, and thereby changing 
the uptake kinetics by hepatic phagocytes. [236, 273] Additionally, the spleen clears 
foreign materials by non-phagocytic filtration mechanisms and thereby does not depend on 
opsonization kinetics. [274, 275] It was shown that the nanoparticles with a size greater 
than 100 nm are cleared more efficiently by the spleen than the smaller nanoparticles. 
Clearance mediated by the spleen also depends on the surface coating of polymeric 
nanoparticles with particles coated with hydrophilic polymers cleared by the spleen in 
greater amounts than uncoated particles for all sizes. [275] When tested for in vitro uptake 
of nanoparticles by splenic white cells in the presence or absence of serum, the uptake of 
coated nanoparticles was significantly lower compared to the uncoated ones, suggesting 
that the increased splenic clearance of nanoparticles with hydrophilic polymer coating is 
not due to the phagocytic activity of the spleen. Additionally, cell uptake was higher for 
any size or coating of the particles studied in the absence of serum, indicating that specific 
opsonization by serum proteins cannot account for higher clearance of coated nanoparticles 
by the spleen. Furthermore, for all nanoparticles’ sizes studied, approximately 50% of the 
coated particles cleared by the spleen after 24 hours of injection were not associated with 
splenic cells, validating the in vitro uptake results by splenic white cells and indicating 
non-phagocytic clearance by the spleen. [275] 
The spleens of the mice injected with nanoclusters and PEGylated nanoclusters 
were stained with H&E, F4/80 macrophage stain and silver stain (Figure 4.10 and Figure 
4.11). In the images on the right hand side, the white pulp area is marked by the black 
circles. For the mice injected with nanoclusters, silver-stained images revealed scant 
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presence of nanoparticles in the marginal zone area between the white pulp and red pulp 
(Figure 4.10). Conversely, PEGylated nanoclusters accumulated heavily in the red pulp 
one day post injection (Figure 4.11). The marginal zone of the spleen is equipped with 
specialized subsets of macrophages, B-cells and dendritic cells, whereas the red pulp 
section of the spleen is dedicated to the filtering of blood. [276] The evidence that only a 
scant amount of nanoclusters were present in marginal zone for the mice injected with 
nanoclusters supports the previous literature that the major role of the spleen in clearance 
is not dependent on phagocytosis. Considerably high accumulation of PEGylated 
nanoclusters in the red pulp further supports the clearance by filtering mechanism rather 








Figure 4.10 H&E (top panel), mouse macrophage (F4/80) stain (middle panel) and silver 
stain (bottom panel) images of the mouse spleen one day after intravenous 
injection of nanoclusters. Black lines in the images at right highlight white 







Figure 4.11 H&E (top panel), mouse macrophage (F4/80) stain (middle panel) and silver 
stain (bottom panel) images of the mouse spleen one day after intravenous 
injection of PEGylated nanoclusters. Black lines in the images at right 









To test the hypothesis that clearance of nanoclusters observed from the liver within 
the first week is due to fast clearance from LSECs, in vitro cell clearance studies using 
main hepatic phagocytes – mouse macrophage cells (J774A.1) and mouse liver sinusoidal 
endothelial cells (LSECs) – was performed. Small number of either type of cells were 
plated and loaded with nanoclusters before observing clearance of nanoclusters over a 
period of 7 days. The exocytosis of nanoparticles depends on many factors including size, 
[140, 154, 155, 277] surface coating,[142, 145, 150, 278-280] incubation 
concentration[148, 156] and incubation time[154, 281-283] of nanoparticles along with 
cell type,[151], [152, 153] and presence or absence of serum during exocytosis[143, 151]. 
To mimic in vivo exposure of nanoclusters, LSECs and J774A.1 cells were incubated with 
0.2 mg Au/mL of nanoclusters (0.4 mg Au being diluted with @ 2 mL blood in mice 
circulation resulting in 0.2 mg Au/mL being exposed to RES cells). Additionally, the 
nanoclusters would be in contact with 100% serum after intravenous injection and being 
coated with serum proteins. To ensure the serum coating of nanoclusters for in vitro study, 
the nanoclusters were preincubated with FBS before adding to cells. Exocytosis of the 
nanoclusters from cells was observed after 4 hours of incubation as the circulation of 
nanoparticles in vivo is in the order of a few hours. [132]  
Clearance of nanoparticles from LSECs was confirmed by statistically significant 
decrease in the area under the curve (AUC) of the extinction spectra for nanoclusters-
loaded cells on fourth and seventh day of clearance compared to the cells loaded with 
nanoparticle before any exocytosis (day 0) (Figure 4.12). Interestingly, no decrease in AUC 
values was observed during seven-day clearance period for J774A.1 cells ((Figure 4.12). 
Instead, there was an increase in AUC on day 4 compared to any other time point, which 
may be because of phagocytosis of nanoparticles non-specifically attached to the petri dish 
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by the proliferating macrophages. On day 7, the AUC again decreased suggesting the 
ongoing exocytosis from macrophages, however, not statistically significant compared to 
day 0. These findings suggests that although the macrophages do exocytose the 
nanoparticles during the first week, the net effect of gold clearance observed for the in vivo 
study (Figure 4.4) is not due to exocytosis from macrophages as the macrophages would 
also actively phagocytose other dying cells loaded with nanoparticles. On the other hand, 
not active in phagocytosis, LSECs uptake nanoclusters based on clathrin-mediated 
endocytosis followed by quick exocytosis resulting in significant clearance in gold from 
the liver during the first week.  
Furthermore, macrophages engulf more than two-times the amount of nanoclusters 
compared to LSECs as seen by AUC for these cells right after the incubation with 
nanoclusters. This suggests that macrophages are still the main phagocytes in clearing up 
bulk of injected nanoclusters and the absence of clearance during second week post 
administration of nanoclusters in mice is likely due to majority of gold being sequestered 





Figure 4.12 Average spectrum of LSECs (a) and J774A.1 (b) cells loaded with gold 
nanoclusters at different time points. (c) Area under the extinction curves for 
LSECs and J774A.1 cells with nanoclusters at different time points. 
Statistically different data (p-value < 0.05 in t-test) is marked by * (different 




An interesting pattern was observed in the proliferation of LSECs and macrophages 
during the clearance study. Macrophage (J774A.1) cells showed initial increase in 
proliferation during the incubation of nanoparticles (day 0) compared to control cells, 
however, at day 1 the number of cells-loaded with nanoclusters were less compared to 
control cells possibly resulting from the death of few macrophages due to engulfing large 
number of nanoclusters. On day 4 however the macrophage cells loaded with nanoclusters 
catch up with control cells and there is no difference in proliferation compared to control 
cells from thereon.  
 
Proliferation pattern of LSECs loaded with nanoclusters was quite different 
compared to macrophages. No significant change in the number of cells loaded with 
nanoclusters compared to control cells was observed during nanoclusters incubation (day 
0) or the day after. However, LSECs loaded with nanoclusters show statistically significant 
increase compared to control cells on day 4 and day 7. This observation is in accordance 
with the natural role of the liver endothelial cells. It is well known that LSECs facilitates 
liver regeneration after partial hepatectomy or liver injury due to toxins. [284] The 
treatment of nanoclusters is probably triggering the same response of LSECs to increase 
proliferation in response to the potential “toxin attack” and thereby showing two-fold 




    
Figure 4.13 Total number of LSECs or J774A.1 cells during clearance the study. 
Statistically different data compared to control (t-test, p-value < 0.05) is 
marked by *. 
 
The cell viability of nanoclusters-loaded cells was comparable with the control cells 
as revealed by fluorescence images of cells stained with Calcein AM (Figure 4.14, Figure 
4.15, Figure 4.16, and Figure 4.17). As J774A.1 cells are harvested by scrapping, gold 
nanoclusters non-specifically attached to the petri dish is seen in the background of the 
bright-field and dark-field images along with the cells for day 0 and day1 images. The 
nanoparticles in the background disappear for day 4 as the proliferating macrophages are 
probably engulfing the non-specifically attached nanoparticles in the culture plate. This 
also supports the finding that at day 4, AUC for extinction spectra is higher compared to 




Figure 4.14 Control LSECs during the clearance study. Images in the middle show 





Figure 4.15 LSECs loaded with nanoclusters during the clearance study. Images in the 
middle show fluorescence due to Calcein AM staining reflecting cell 









Figure 4.16 Control J774A.1 cells during the clearance study. Images in the middle 
show fluorescence due to Calcein AM staining reflecting cell viability. 





Figure 4.17 J774A.1 cells loaded with nanoclusters during the clearance study. Images 
in the middle show fluorescence due to Calcein AM staining reflecting cell 









In this study, we have evaluated the pharmacokinetics of biodegradable gold 
nanoclusters in mice. In vitro model proposed using the major phagocytes of the liver 
accurately decipher the pattern of in vivo clearance of nanoparticles from the liver. Liver 
sinusoidal endothelial cells uptake nanoparticles via endocytosis with fast exocytosis 
kinetics facilitating early clearance of nanoparticles from the liver. Hepatic macrophages 
engulf other cells loaded with nanoparticles giving rise in the presence of nanoparticles in 
macrophages during the second week post nanoclusters administration. As in vitro model 
closely resembles the clearance patterns of the liver, screening of contrast agents with 
clinical translation potential can be expedited using the fast and less expensive in vitro 
testing before pursuing more labor-intensive in vivo evaluations. The feasibility to screen 
potential contrast agents with in vitro model proposed in this study can free up time and 
resources to enable testing of multiple potential agents and facilitate quick optimization 
instead of waiting to get results from a time-intensive animal study. The study presented in 
this chapter will dramatically enhance the number of successful contrast agents being tested 
in preclinical studies, giving rise to the clinical translation of these promising agents.  
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Chapter 5: Final Remarks 
5.1 CONCLUSIONS 
This dissertation contributes significantly to the development of the contrast agents 
suitable for clinical applications by directly addressing the major challenges in translation 
of nanoparticle-based contrast agents to the clinic. The molecular-specific contrast agents 
based on gold nanorods developed in chapter 2 offer directional conjugation of antibodies 
to the nanorod surface, facilitating efficient targeting along with shielding the Fc portion 
of the antibodies to increase blood half-life by reducing uptake by immune cells via Fc 
receptors. The robust technique of producing molecular-specific nanorods not only 
provides an increase in the signal-to-background ratio by enhancing molecular-specific 
uptake and facilitating efficient accumulation in the diseased region through enhanced 
blood residence time but also offers high selectivity during optical and photoacoustic 
imaging. In vivo imaging feasibility is demonstrated using noninvasive photoacoustic 
imaging of cells labeled with molecular-specific nanorods. Photoacoustic (PA) imaging 
combined with ultrasound imaging offers a safe, cost-effective, and robust technique to 
obtain functional and morphological information. PA imaging has great potential for 
clinical use due to multiple advantages including a lack of ionizing radiation or radioactive 
agents, an imaging depth in centimeters with near infrared contrast agents, and feasibility 
for molecular-specific imaging as demonstrated in the chapter 2 of this dissertation. The 
molecular-specific agents developed in this chapter facilitate translational research and 
foster understanding of disease dynamics by providing the capability for efficient 
molecular-specific imaging of the diseased site. 
Chapter 3 of this dissertation furthers current imaging capabilities by offering a 
solution to avoid plasmon coupling of gold nanorods upon cell uptake and enabling 
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sensitive multiplex imaging to track cells. The near-IR contrast agents developed in this 
project enable tracking of cells with very high sensitivity (detecting a few cells per unit 
imaging volume), which in turn facilitates an understanding of dynamics played by 
different cells in the onset, progression, and reoccurrence of a disease. The added capability 
of fluorescence enables ex vivo validation of the tissue after in vivo imaging during 
translational studies.  
Chapter 4 correlates in vivo distribution of the biodegradable gold nanoclusters with 
in vitro study and proposes a cell culture model that can be used to predict in vivo fate of 
promising contrast agents in a fast, cost-efficient, and reliable way. The in vitro model 
would not only predict biodistribution and clearance patterns in major MPS organs but also 
enhance the number of these agents going to the clinical trial phase and eventually to the 
clinic.  
The contrast agents developed in this dissertation can facilitate an understanding of 
biological events at the molecular level, the role of immune cells, cellular distribution, and 
trafficking in different disease states. Furthermore, the tools proposed in this dissertation 
will enhance the clinical translation of the promising contrast agents by reducing time to 
evaluate their biological fate, offering quick feedback for further optimization as well as 





5.2 FUTURE DIRECTIONS 
 
Because the current tracking of cells using silica-coated gold nanorods images the 
contrast agent – gold nanorods – within the cells, the imaging does not directly assess cell 
viability in vivo. Moreover, the contrast dilution with proliferation may prohibit long-term 
tracking. Using a strategy similar to reporter gene in combination with nanoparticles can 
possibly enable highly sensitive detection of proliferative cells using the noninvasive 
photoacoustic imaging described in this dissertation. [285-287]  
For cell-based therapy and imaging using immune cells, enhancing the tumor 
homing properties of the cells during ex vivo expansion and then loading them with 
nanoparticles can increase the capacity of the immune cells to reach the tumor and enhance 
their therapeutic efficacy along with imaging sensitivity. [251] 
Successful introduction of nanoparticles-based diagnostic agents to the clinic 
depends heavily on in vivo detection sensitivity as well as the clearance of the diagnostic 
agents after the imaging. The studies in this dissertation demonstrate an efficient way to 
correlate in vivo fate of nanoparticles using an in vitro model. A revolutionary approach to 
ensure final clearance of nanoparticles from the MPS organs is the development of “smart” 
nanoparticles possibly decorated with biological moieties that direct the intracellular 
machinery of the cells of the MPS organs to exocytose the engulfed nanoparticles within a 
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